Prospective surgical-pathological study of disease-free squamous cell carcinoma of the cervix: A Gynecologic C

Gynecologic Oncology 38, 352-357 DOI: 10.1016/0090-8258(90)90072-s

Citation Report

#	Article	IF	CITATIONS
1	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 341.	0.6	4
2	The morphology and distribution of lymph node metastases in stage IB/IIA cervical carcinoma: relationship to prognosis. International Journal of Gynecological Cancer, 1991, 1, 233-237.	1.2	11
3	Proposal of a modified FIGO 1985 classification of stages I and II cancer of the uterine cervix. Gynecologic Oncology, 1992, 47, 210-215.	0.6	2
4	Prognostic significance of polymerase chain reaction detected human papillomavirus of tumors and lymph nodes in surgically treated stage IB cervical cancer. Gynecologic Oncology, 1992, 47, 343-347.	0.6	54
5	Transvaginal sonography as an aid in the clinical staging of carcinoma of the cervix. Journal of Clinical Ultrasound, 1992, 20, 283-287.	0.4	17
6	Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix a gynecologic oncology group study. Cancer, 1992, 69, 1750-1758.	2.0	163
7	Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer, 1992, 69, 2796-2806.	2.0	267
8	Radical hysterectomy for invasive cervical cancer: A 25â€year prospective experience with the Miami technique. Cancer, 1993, 71, 1422-1436.	2.0	137
9	Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection — an analysis with mathematical statistics. International Journal of Gynecological Cancer, 1993, 3, 219-225.	1.2	22
10	Radiotherapy versus Radical Surgery for Gynecologic Neoplasms: Carcinomas of the Cervix and Vulva. Frontiers of Radiation Therapy and Oncology, 1993, 27, 130-142.	1.4	9
11	EXPRESSION OF NM23-H1 GENE IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX CORRELATES WITH 5-YEAR SURVIVAL. International Journal of Oncology, 1994, 5, 1455-7.	1.4	4
12	Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer. Cancer, 1994, 74, 2497-2501.	2.0	36
13	Human papillomavirus DNA in cervical carcinoma—correlation with clinical data and influence on prognosis. International Journal of Cancer, 1994, 59, 322-326.	2.3	40
14	Diagnosis and surgical treatment of cervical cancer. Critical Reviews in Oncology/Hematology, 1994, 17, 181-231.	2.0	11
15	Treatment options in stage IB cervical cancer: Radical hysterectomy and radiotherapy. Seminars in Radiation Oncology, 1994, 4, 34-40.	1.0	12
16	Preservation of multiple oncogenic human papillomavirus types in recurrences of early-stage cervical cancers. American Journal of Obstetrics and Gynecology, 1994, 170, 1230-1233.	0.7	2
17	Preservation of multiple oncogenic human papillomavirus types in recurrences of early-stage cervical cancers. American Journal of Obstetrics and Gynecology, 1994, 170, 1230-1233.	0.7	1
18	Female genital tract cancer. Cancer, 1995, 75, 270-294.	2.0	142

TITATION REDOD

	CITATIO	N REPORT	
#	Article	IF	Citations
19	Age, substance abuse, and survival of patients with cervical carcinoma. Cancer, 1995, 75, 2530-2538.	2.0	29
20	Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer, 1995, 76, 1978-1986.	2.0	107
21	Node-positive cervical cancer: Impact of pelvic irradiation and patterns of failure. International Journal of Radiation Oncology Biology Physics, 1995, 31, 31-36.	0.4	74
22	Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update for a nonrandomized comparison. International Journal of Radiation Oncology Biology Physics, 1995, 31, 703-716.	0.4	151
23	Prognostic Factors in Cancer. , 1995, , .		35
25	Lymph node metastases, cell type, age, HPV status and type, neoadjuvant chemotherapy and treatment failures in cervical cancer. International Journal of Gynecology and Obstetrics, 1995, 49, S17-S25.	1.0	5
26	Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiotherapy and Oncology, 1995, 35, 107-117.	0.3	144
27	Comparison of diagnostic studies in the pretreatment evaluation of stage Ib carcinoma of the cervix. Academic Radiology, 1996, 3, S44-S46.	1.3	9
28	Mature Results of a Phase II Trial of Concomitant Cisplatin/Pelvic Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Cervix. Gynecologic Oncology, 1996, 61, 416-422.	0.6	45
29	Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Human Pathology, 1996, 27, 904-911.	1.1	75
30	Tumor angiogenesis: An independent prognostic parameter in cervical cancer. American Journal of Obstetrics and Gynecology, 1996, 174, 126-131.	0.7	103
31	Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma Journal of Clinical Oncology, 1996, 14, 111-118.	0.8	139
32	Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenectomy. American Journal of Obstetrics and Gynecology, 1996, 174, 1763-1768.	0.7	124
33	Surgically defined prognostic parameters in patients with early cervical carcinoma: A multivariate survival tree analysis. , 1996, 78, 1438-1446.		148
34	Disease-free interval and recurrence pattern after the Okabayashi variant of Wertheim's radical hysterectomy for stage IB and IIA cervical carcinoma. International Journal of Gynecological Cancer, 1996, 6, 120-127.	1.2	34
35	Lymphvascular invasion in stage IB cervical carcinoma: prognostic significance and role of adjuvant radiotherapy. International Journal of Gynecological Cancer, 1996, 6, 208-212.	1.2	6
36	Prognosis and prognostic factors in node-negative cervix cancer. International Journal of Gynecological Cancer, 1996, 6, 477-482.	1.2	13
37	Radiological Evaluation of Lymph Node Metastases in Patients With Cervical Cancer. JAMA - Journal of the American Medical Association, 1997, 278, 1096.	3.8	231

#	Article	IF	CITATIONS
38	Identification of High-Risk Groups among Node-Positive Patients with Stage IB and IIA Cervical Carcinoma. Gynecologic Oncology, 1997, 64, 463-467.	0.6	57
39	Prognostic Factors in Patients with Bulky Stage IB or IIA Cervical Carcinoma Undergoing Neoadjuvant Chemotherapy and Radical Hysterectomy. Gynecologic Oncology, 1997, 64, 456-462.	0.6	55
40	Stage IB and IIA Cervical Cancer with Negative Lymph Nodes: The Role of Adjuvant Radiotherapy after Radical Hysterectomy. Gynecologic Oncology, 1997, 66, 31-35.	0.6	76
42	Adjuvant Therapy in Gynecologic Malignancies. Surgical Oncology Clinics of North America, 1997, 6, 813-830.	0.6	10
43	Postoperative radiation for cervical cancer with pathologic risk factors. International Journal of Radiation Oncology Biology Physics, 1997, 37, 833-838.	0.4	29
44	Analysis of prognostic factors in stage IIB–IVA cervical carcinoma treated with radiation therapy: Value of computed tomography. International Journal of Radiation Oncology Biology Physics, 1997, 37, 1071-1077.	0.4	20
45	Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. , 1997, 80, 1234-1240.		48
46	Influence of Quantity of Lymph–Vascular Space Invasion on the Risk of Nodal Metastases in Women with Early-Stage Squamous Cancer of the Cervix. Gynecologic Oncology, 1998, 68, 220-225.	0.6	83
47	Close Vaginal Margins as a Prognostic Factor after Radical Hysterectomy. Gynecologic Oncology, 1998, 68, 229-232.	0.6	80
48	Lymphovascular Space Involvement in Cervical Cancer: An Independent Risk Factor. Gynecologic Oncology, 1998, 68, 219.	0.6	13
49	Indication and Efficacy of Radiation Therapy Following Radical Surgery in Patients with Stage IB to IIB Cervical Cancer. Gynecologic Oncology, 1998, 70, 61-64.	0.6	17
50	Early invasive carcinoma of the cervix (3 to 5 mm invasion): Risk factors and prognosis. American Journal of Obstetrics and Gynecology, 1998, 178, 62-65.	0.7	94
51	The influence of vascular space involvement on the prognosis of patients with stage IB cervical carcinoma. , 1998, 82, 689-696.		21
52	Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis. International Journal of Gynecological Cancer, 1998, 8, 78-84.	1.2	59
53	Tumor Size, Irradiation Dose, and Long-Term Outcome of Carcinoma of Uterine Cervix. International Journal of Radiation Oncology Biology Physics, 1998, 41, 307-317.	0.4	222
54	Fertility options for patients with stages ia2 and ib cervical cancer: presentation of two cases and discussion of technical and ethical issues. Obstetrics and Gynecology, 1998, 92, 656-658.	1.2	7
55	Prognosis-predicting system based on factors related to survival of cervical carcinoma. International Journal of Gynecology and Obstetrics, 1998, 63, 163-167.	1.0	23
56	FERTILITY OPTIONS FOR PATIENTS WITH STAGES IA2 AND IB CERVICAL CANCER. Obstetrics and Gynecology, 1998, 92, 656-658.	1.2	5

#	Article	IF	Citations
58	Detection of Human Papillomavirus Types 16 and 18 mRNA in Peripheral Blood of Advanced Cervical Cancer Patients and Its Association With Prognosis. Journal of Clinical Oncology, 1999, 17, 1391-1391.	0.8	67
59	Vascular Endothelial Growth Factor in Cervical Carcinoma. Obstetrics and Gynecology, 1999, 93, 761-765.	1.2	1
60	Cervical Carcinoma: Can Dynamic Contrast-enhanced MR Imaging Help Predict Tumor Aggressiveness?. Radiology, 1999, 210, 217-220.	3.6	31
62	Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix stage IB and IIA treated with preoperative irradiation and surgery. International Journal of Radiation Oncology Biology Physics, 1999, 45, 645-651.	0.4	24
63	CD44v6 expression is an independent prognostic factor in node-negative FIGO stage IB cervical carcinoma. International Journal of Gynecological Cancer, 1999, 9, 160-165.	1.2	8
64	The prognostic significance of p53, mdm2, c-erbB-2, cathepsin D, and thrombocytosis in stage IB cervical cancer treated by primary radical hysterectomy. International Journal of Gynecological Cancer, 1999, 9, 198-205.	1.2	19
65	Surgically-treated early cervical cancer: Prognostic factors and the significance of depth of tumor invasion. International Journal of Gynecological Cancer, 1999, 9, 212-219.	1.2	41
66	Clinical significance of tumor size in stage IB and II carcinoma of the uterine cervix. International Journal of Gynecological Cancer, 1999, 9, 421-426.	1.2	17
67	A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study. Gynecologic Oncology, 1999, 73, 177-183.	0.6	1,082
68	Tumor Size, Depth of Invasion, and Grading of the Invasive Tumor Front Are the Main Prognostic Factors in Early Squamous Cell Cervical Carcinoma. Gynecologic Oncology, 1999, 74, 245-251.	0.6	162
69	The Prognostic Factors for Patients with Early Cervical Cancer Treated by Radical Hysterectomy and Postoperative Radiotherapy. Gynecologic Oncology, 1999, 75, 328-333.	0.6	112
70	A Limited Role for Adjuvant Radiotherapy after the Wertheim/Okabayashi Radical Hysterectomy for Cervical Cancer Confined to the Cervix. Gynecologic Oncology, 1999, 75, 233-237.	0.6	28
72	The impact of intraoperative autologous blood transfusion during type III radical hysterectomy for early-stage cervical cancer. American Journal of Obstetrics and Gynecology, 1999, 181, 1310-1316.	0.7	45
73	Biology of cervical carcinoma. , 1999, 16, 212-216.		8
74	Management of microinvasive cervical cancers. , 1999, 16, 228-231.		13
75	Surgical management of stage IB-IIA cervical carcinoma. , 1999, 16, 232-235.		12
76	Adjuvant small field pelvic radiation for patients with high risk, Stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. , 1999, 86, 2059-2065.		30
77	Is radical trachelectomy a safe alternative to radical hysterectomy for patients with Stage IA-B carcinoma of the cervix?. , 1999, 86, 2273-2279.		207

#	Article	IF	CITATIONS
78	Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma. New England Journal of Medicine, 1999, 340, 1154-1161.	13.9	1,734
79	Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase l–Il trial. European Journal of Cancer, 1999, 35, 946-952.	1.3	210
80	Stage IA1 cervical adenocarcinoma: definition and treatment. Obstetrics and Gynecology, 1999, 93, 219-222.	1.2	45
81	Vascular endothelial growth factor in cervical carcinoma. Obstetrics and Gynecology, 1999, 93, 761-765.	1.2	38
82	Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984-1996). Radiotherapy and Oncology, 1999, 51, 161-167.	0.3	55
83	Enhanced Expression of Thymidylate Synthase May Be of Prognostic Importance in Advanced Cervical Cancer. Oncology, 1999, 57, 50-54.	0.9	29
84	Stage IA1 Cervical Adenocarcinoma. Obstetrics and Gynecology, 1999, 93, 219-222.	1.2	20
85	Recurrence and Survival Analyses of 1,115 Cervical Cancer Patients Treated with Radical Hysterectomy. Gynecologic and Obstetric Investigation, 1999, 47, 127-132.	0.7	41
86	Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. Journal of Clinical Oncology, 2000, 18, 1606-1613.	0.8	2,012
87	Pregnancy and Malignancy: Balancing the Issues. Journal of Obstetrics and Gynaecology Canada, 2000, 22, 47-55.	0.1	1
88	Laparoscopic vaginal radical trachelectomy. , 2000, 88, 1877-1882.		383
89	Adjuvant therapy for high-risk, early stage cervical cancer. Seminars in Radiation Oncology, 2000, 10, 51-60.	1.0	35
90	High-Risk Group in Node-Positive Patients with Stage IB, IIA, and IIB Cervical Carcinoma after Radical Hysterectomy and Postoperative Pelvic Irradiation. Gynecologic Oncology, 2000, 77, 305-309.	0.6	110
91	Surgical Stapling Technique for Radical Hysterectomy: Survival, Recurrence, and Late Complications. Gynecologic Oncology, 2000, 79, 281-283.	0.6	6
92	Effect of MRI on Therapeutic Decisions in Invasive Cervical Carcinoma. Gynecologic Oncology, 2000, 79, 485-489.	0.6	17
93	The Abandoned Radical Hysterectomy: A Gynecologic Oncology Group Study. Gynecologic Oncology, 2000, 79, 350-356.	0.6	41
94	The role of MR imaging in invasive cervical carcinoma. European Radiology, 2000, 10, 256-270.	2.3	100
95	Randomized Trial of Neoadjuvant Cisplatin, Vincristine, Bleomycin, and Radical Hysterectomy Versus Radiation Therapy for Bulky Stage IB and IIA Cervical Cancer. Journal of Clinical Oncology, 2000, 18, 1740-1747	0.8	124

ARTICLE IF CITATIONS # Intent-to-treat analysis of stage lb and lla cervical cancer in the United States: radiotherapy or surgery 1.2 21 96 1988–1995. Obstetrics and Gynecology, 2001, 97, 248-254. Cone biopsy and pathologic findings at radical hysterectomy in stage I cervical carcinoma 1. Obstetrics 1.2 and Gynecology, 2001, 98, 779-782. 98 CERVICAL CARCINOMA. Obstetrics and Gynecology Clinics of North America, 2001, 28, 727-742. 2 0.7 Metastatic Lymph Nodes in Patients with Cervical Cancer: Detection with MR Imaging and FDG PET. 99 Radiology, 2001, 218, 776-782. Prognostic Factors and Failure Pattern in Lymph Node-Negative Stage IB and II Cervical Carcinoma 100 Treated with Radical Hysterectomy and Postoperative Irradiation. Gynecologic and Obstetric 0.7 10 Investigation, 2001, 52, 13-17. Cone Biopsy and Pathologic Findings at Radical Hysterectomy in Stage I Cervical Carcinoma. Obstetrics and Gynecology, 2001, 98, 779-782. 1.2 Postoperative adjuvant therapy in early invasive cervical cancer patients with histopathologic 102 1.2 6 high-risk factors. International Journal of Gynecological Cancer, 2001, 11, 475-482. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. 0.8 1.205 Statistics in Medicine, 2001, 20, 2865-2884. Prognostic value of the colposcopic tumor size in stage IB squamous cervical cancer. Journal of 104 0.8 2 Surgical Oncology, 2001, 76, 133-137. Ten-Year Survival of Patients with Locally Advanced, Stage IB–IIB Cervical Cancer after Neoadjuvant Chemotherapy and Radical Hysterectomy. Gynecologic Oncology, 2001, 82, 88-93. Neoadjuvant Chemotherapy for Patients Younger Than 50 Years with High-Risk Squamous Cell 106 17 0.6 Carcinoma of the Cervix. Gynecologic Oncology, 2001, 83, 263-267. Intent-to-Treat Analysis of Stage Ib and IIa Cervical Cancer in the United States. Obstetrics and Gynecology, 2001, 97, 248-254. 1.2 MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical 109 1.4 4 carcinomas: Correlation with clinical outcome. International Journal of Oncology, 2002, 20, 1041. Retrospective Analysis of Postoperative Radiotherapy for Node-negative Cervical Carcinoma with Stage IB-IIB Disease. Japanese Journal of Clinical Oncology, 2002, 32, 255-261. Blood Transfusion and the Risk of Recurrence in Squamous Cell Carcinoma of the Cervix. American 111 0.6 25 Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 398-403. Histopathologic Correlation of High-Resolution Magnetic Resonance Imaging of Human Cervical Tissue Samples at 3 Tesla. Investigative Radiology, 2002, 37, 381-385. Traditional management of invasive cervical cancer. Obstetrics and Gynecology Clinics of North 113 0.7 22 America, 2002, 29, 645-657. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma 1.3 of the cervix. European Journal of Cancer, 2002, 38, 1987-1991.

#	Article	IF	CITATIONS
117	Cáncer voluminoso del cuello uterino en estadios I y II: un dilema terapéutico. EMC - GinecologÃa-Obstetricia, 2002, 38, 1-4.	0.0	0
118	Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer. Oncologist, 2002, 7, 342-347.	1.9	203
119	Gynecologic brachytherapy I: Proper incorporation of brachytherapy into the current multimodality management of carcinoma of the cervix. Seminars in Radiation Oncology, 2002, 12, 40-52.	1.0	19
121	Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and Ila is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989-1991. International Journal of Gynecological Cancer, 2002, 12, 158-170.	1.2	20
122	Surgical treatment of low stage cervical carcinoma: Back to the old days?. International Journal of Gynecological Cancer, 2002, 12, 429-434.	1.2	9
123	Immunohistochemical expression of p53, bcl-2, and p21WAF1/CIP1 in early cervical carcinoma: Correlation with clinical outcome. International Journal of Gynecological Cancer, 2002, 12, 290-298.	1.2	15
124	The relevance of oncogenes as prognostic markers in cervical cancer. International Journal of Gynecological Cancer, 2002, 12, 465-474.	1.2	17
125	The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2002, 52, 33-48.	0.4	117
126	Parametrial Spread of Cervical Cancer in Patients with Negative Pelvic Lymph Nodes. Gynecologic Oncology, 2002, 84, 252-257.	0.6	65
127	Intraoperative Measurements to Determine the Extent of Radical Hysterectomy. Gynecologic Oncology, 2002, 87, 281-286.	0.6	16
128	The correlation of preoperative CT, MR imaging, and clinical staging (FIGO) with histopathology findings in primary cervical carcinoma. European Radiology, 2003, 13, 2338-2345.	2.3	119
129	Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. Journal of Cancer Research and Clinical Oncology, 2003, 129, 521-530.	1.2	122
130	Population-based survival for cervical cancer in Singapore, 1968-1992. American Journal of Obstetrics and Gynecology, 2003, 188, 324-329.	0.7	10
131	Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecologic Oncology, 2003, 88, 419-423.	0.6	165
132	Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecologic Oncology, 2003, 89, 140-147.	0.6	64
133	Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Groupâ~†. Gynecologic Oncology, 2003, 89, 343-353.	0.6	246
134	Laparoscopic-assisted radical vaginal hysterectomy (LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecologic Oncology, 2003, 90, 505-511.	0.6	144
135	Laparoscopic lymphadenectomy and laparoscopic-assisted vaginal hysterectomy. Gynecologic Oncology, 2003, 90, 503-504.	0.6	13

#	Article	IF	CITATIONS
136	Imaging in cervical cancer. Cancer, 2003, 98, 2028-2038.	2.0	121
137	Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediatedin vitrovaccination. International Journal of Cancer, 2003, 104, 345-353.	2.3	18
138	Nonoperative assessment of nodal status for locally advanced cervical squamous cell carcinoma treated by radiotherapy with regard to patterns of treatment failure. International Journal of Radiation Oncology Biology Physics, 2003, 55, 354-361.	0.4	13
139	Microinvasive squamous cell cervical carcinoma. Critical Reviews in Oncology/Hematology, 2003, 48, 251-261.	2.0	19
140	Use of small pelvic field instead of whole pelvic field in postoperative radiotherapy for node-negative, high-risk stages I and II cervical squamous cell carcinoma. International Journal of Gynecological Cancer, 2003, 13, 170-176.	1.2	13
141	Does the density of lymphatic vascular space invasion affect the prognosis of stage Ib and IIA node negative carcinoma of the cervix?. International Journal of Gynecological Cancer, 2003, 13, 313-316.	1.2	20
142	Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy. International Journal of Gynecological Cancer, 2003, 13, 657-663.	1.2	66
143	Surgical treatment of lymph node metastases in stage IB cervical cancer: The laterally extended parametrectomy (LEP) procedure. International Journal of Gynecological Cancer, 2003, 13, 647-651.	1.2	22
144	Cervical cancer. Lancet, The, 2003, 361, 2217-2225.	6.3	831
145	Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer. Obstetrics and Gynecology, 2003, 102, 612-619.	1.2	45
148	Gynaecology Case Reports. Journal of Obstetrics and Gynaecology, 2003, 23, 81-92.	0.4	14
149	Prognostic value of lymphovascular space invasion determined with hematoxylin–eosin staining in early stage cervical carcinoma: results of a multivariate analysis. Annals of Oncology, 2003, 14, 1511-1517.	0.6	77
150	Combined-Modality Therapy of Locally Advanced Cervical Cancer. Journal of Clinical Oncology, 2003, 21, 211s-217.	0.8	26
151	Lymphovascular and Perineural Invasion in the Parametria. Obstetrics and Gynecology, 2003, 102, 612-619.	1.2	22
152	Docetaxel as Neoadjuvant Chemotherapy in Patients With Advanced Cervical Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 477-482.	0.6	15
153	Stage Ia-IIa Cancer of the Cervix. Cancer Journal (Sudbury, Mass), 2003, 9, 395-403.	1.0	2
154	Use of small pelvic field instead of whole pelvic field in postoperative radiotherapy for node-negative, high-risk stages I and II cervical squamous cell carcinoma. International Journal of Gynecological Cancer, 2003, 13, 170-176.	1.2	15
155	Histopathologic parameters of prognosis in cervical cancer – a review. International Journal of Gynecological Cancer, 2004, 14, 741-750.	1.2	2

#	Article	IF	CITATIONS
156	MANEJO DEL CÃNCER CERVICOUTERINO IB2-IIA. Revista Chilena De Obstetricia Y Ginecologia, 2004, 69, 384.	0.1	0
157	Histopathological validation of the sentinel node concept in cervical cancer. Annals of Oncology, 2004, 15, 870-874.	0.6	50
158	Usefulness of Preoperative Chemoradiation in Locally Advanced Cervical Carcinoma. Gynecologic and Obstetric Investigation, 2004, 57, 93-99.	0.7	10
159	HPV and histological status of pelvic lymph node metastases in cervical cancer: a prospective study. Journal of Clinical Pathology, 2004, 57, 472-476.	1.0	21
160	Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. International Journal of Oncology, 2004, 24, 1175.	1.4	2
161	Identification of Micrometastases in Histologically Negative Lymph Nodes of Early-Stage Cervical Cancer Patients. Obstetrics and Gynecology, 2004, 103, 1204-1210.	1.2	78
162	Letters to the Editor. International Journal of Gynecological Cancer, 2004, 14, 178-179.	1.2	2
163	Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy. International Journal of Gynecological Cancer, 2004, 14, 286-292.	1.2	43
164	Histopathologic parameters of prognosis in cervical cancer - a review. International Journal of Gynecological Cancer, 2004, 14, 741-750.	1.2	101
165	Do the pelvic lymph nodes predict the parametrial status in cervical cancer stages IB-IIA?. International Journal of Gynecological Cancer, 2004, 14, 832-840.	1.2	26
166	Prospective phase I/II study of irradiation and concurrent chemotherapy for recurrent cervical cancer after radical hysterectomy. International Journal of Gynecological Cancer, 2004, 14, 860-864.	1.2	9
167	Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 591-597.	1.3	10
168	Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Seminars in Oncology, 2004, 31, 17-24.	0.8	34
169	Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecologic Oncology, 2004, 92, 40-46.	0.6	32
170	Extended experience in the use of laparoscopic ultrasound to detect pelvic nodal metastasis in patients with cervical carcinoma. Gynecologic Oncology, 2004, 92, 784-788.	0.6	14
171	Detection of pelvic lymph node micrometastasis in stage IA2–IB2 cervical cancer by immunohistochemical analysis. Gynecologic Oncology, 2004, 93, 107-111.	0.6	80
172	Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecologic Oncology, 2004, 93, 458-464.	0.6	159
173	Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecologic Oncology, 2004, 93, 429-434.	0.6	57

#	Article	IF	CITATIONS
174	Depth of cervical stromal invasion as a prognostic factor after radical surgery for early stage cervical cancer. Gynecologic Oncology, 2004, 93, 637-641.	0.6	15
175	Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecologic Oncology, 2004, 94, 61-66.	0.6	92
176	The role of the preoperative serum carcinoembryonic antigen level in early-stage adenocarcinoma of the uterine cervix. Gynecologic Oncology, 2004, 94, 363-367.	0.6	12
177	Surgical–pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?. Gynecologic Oncology, 2004, 94, 249-255.	0.6	29
178	FIGO Stage IB2 cervix cancer and putting all your eggs in one basket. Gynecologic Oncology, 2004, 94, 245-246.	0.6	3
179	A thousand several tongues. Gynecologic Oncology, 2004, 94, 247-248.	0.6	0
180	Prognostic difference of surgical treatment of exophytic versus barrel-shaped bulky cervical cancer. Gynecologic Oncology, 2004, 95, 77-81.	0.6	22
181	Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer. Gynecologic Oncology, 2004, 95, 208-214.	0.6	43
182	Accuracy of pelvic examination in the assessment of patients with operable cervical cancer. American Journal of Obstetrics and Gynecology, 2004, 190, 986-992.	0.7	30
183	Histopathological prognostic factors in patients with cervical cancer treated with radical hysterectomy and postoperative radiotherapy. International Journal of Clinical Oncology, 2004, 9, 503-509.	1.0	17
184	Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma. Cancer, 2004, 101, 671-681.	2.0	45
185	Use of the small pelvic field instead of the classic whole pelvic field in postoperative radiotherapy for cervical cancer: Reduction of adverse events. International Journal of Radiation Oncology Biology Physics, 2004, 60, 258-264.	0.4	26
186	Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecologic Oncology, 2004, , .	0.6	0
187	Optimizing Treatment for Cervical Cancer. American Journal of Cancer, 2004, 3, 215-227.	0.4	5
188	Human Papillomavirus Deoxyribonucleic Acid Sequences and Clinical Outcomes of Cervical Cancer Patients Following Radiotherapy. Taiwanese Journal of Obstetrics and Gynecology, 2004, 43, 20-24.	0.5	1
189	Preoperative Magnetic Resonance Imaging Staging of Uterine Cervical Carcinoma. Journal of Computer Assisted Tomography, 2004, 28, 620-627.	0.5	86
190	Long-Term Clinical Outcomes of Postoperative Pelvic Radiotherapy With or Without Prophylactic Paraaortic Irradiation for Stage I-II Cervical Carcinoma With Positive Lymph Nodes. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 140-148.	0.6	8
191	Advances in the surgical management of invasive cervical cancer. Current Opinion in Obstetrics and Gynecology, 2005, 17, 5-12.	0.9	26

#	Article	IF	CITATIONS
192	Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. International Journal of Radiation Oncology Biology Physics, 2005, 61, 444-449.	0.4	33
193	An evidence-based estimate of the appropriate rate of utilization of radiotherapy for cancer of the cervix. International Journal of Radiation Oncology Biology Physics, 2005, 63, 812-827.	0.4	23
194	Preliminary Results of Consolidation Chemotherapy Following Concurrent Chemoradiation after Radical Surgery in High-risk Early-stage Carcinoma of the Uterine Cervix. Clinical Oncology, 2005, 17, 412-417.	0.6	10
195	Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer. International Journal of Gynecological Cancer, 2005, 15, 573-582.	1.2	25
196	Re: Severe hyponatraemia as a result of primary polydipsia in labour. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 259-259.	0.4	0
197	Re: Severe hyponatraemia as a result of primary polydipsia in labour. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 259-260.	0.4	0
198	Reply to Drs Brown and Morton. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 260-260.	0.4	0
199	Why are we still doing radical hysterectomies for cervical cancer?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 260-261.	0.4	0
200	Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Modern Pathology, 2005, 18, 97-104.	2.9	97
201	Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. International Journal of Gynecological Cancer, 2005, 15, 88-93.	1.2	21
202	The pathology of cervical tumours. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2005, 19, 485-500.	1.4	29
203	Post-hysterectomy radiotherapy in FIGO stage IB–IIB uterine cervical carcinoma. Gynecologic Oncology, 2005, 96, 407-414.	0.6	24
204	Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecologic Oncology, 2005, 96, 490-495.	0.6	43
205	Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical–pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecologic Oncology, 2005, 96, 721-728.	0.6	181
206	Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecologic Oncology, 2005, 96, 799-804.	0.6	197
207	Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: A retrospective case-control surgico-pathological study. Gynecologic Oncology, 2005, 97, 727-732.	0.6	122
208	Sentinel node detection in cervical cancer with 99mTc-phytate. Gynecologic Oncology, 2005, 97, 588-595.	0.6	70
209	Risk grouping in stage IB squamous cell cervical carcinoma. Gynecologic Oncology, 2005, 99, 106-112.	0.6	55

ARTICLE IF CITATIONS Adenoid cystic carcinoma of the cervix. Gynecologic Oncology, 2005, 99, 477-480. 210 0.6 24 Arguments for a magnetic resonance imaging–assisted FIGO staging system for cervical cancer. 1.2 International Journal of Gynecological Cancer, 2005, 15, 573-582. Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. International 214 1.2 28 Journal of Gynecological Cancer, 2005, 15, 88-93. TRATAMIENTO ADYUVANTE DEL CANCER CAMRVICO UTERINO: FACTORES DE RIESGO, INDICACIONES Y 0.1 TRATAMIENTO. Revista Chilena De Obstetricia Y Ginecologia, 2005, 70, 41. The Usefulness of MRI and PET Imaging for the Detection of Parametrial Involvement and Lymph Node 216 0.6 74 Metastasis in Patients with Cervical Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 260-264. Role of Imaging in Pretreatment Evaluation of Early Invasive Cervical Cancer: Results of the Intergroup Študy American College of Radiology Imaging Network 6651–Gynecologic Oncology Group 183. Journal of Clinical Oncology, 2005, 23, 9329-9337. 0.8 Utilization of Diagnostic Studies in the Pretreatment Evaluation of Invasive Cervical Cancer in the United States: Results of Intergroup Protocol ACRIN 6651/GOG 183. Journal of Clinical Oncology, 2005, 218 0.8 68 23, 7454-7459. Clinicopathological Features Influencing Pelvic Lymph Node Metastasis and Vaginal and Parametrial 219 Involvement in Patients with Carcinoma of the Cervix. Gynecologic and Obstetric Investigation, 2005, 19 59, 92-96. Role of Laparoscopic Lymphadenectomy in the Management of Cervical Cancer. Taiwanese Journal of 220 0.5 2 Obstetrics and Gynecology, 2005, 44, 301-313. Association between the mesenchymal compartment of uterovaginal organogenesis and local tumour 5.1 spread in stage IB–IIB cervical carcinoma: a prospective study. Lancet Oncology, The, 2005, 6, 751-756. Detection and quantitation of human papillomavirus DNA in primary tumour and lymph nodes of 222 1.6 24 patients with early stage cervical carcinoma. Journal of Clinical Virology, 2005, 33, 201-205. Early Invasive Cervical Cancer: Tumor Delineation by Magnetic Resonance Imaging, Computed Tomography, and Clinical Examination, Verified by Pathologic Results, in the ACRIN 6651/GOG 183 Intergroup Study. Journal of Clinical Oncology, 2006, 24, 5687-5694. 0.8 281 Management of cervical cancer. European Journal of Surgical Oncology, 2006, 32, 832-837. 225 0.5 57 Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IBâ \in "IIA cervical cancer. European Journal of Surgical Oncology, 2006, 32, 1226-1230. Survival Benefits of Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy in 227 1.1 17 Locally Advanced Chemoresistant Cervical Cancer. Journal of Korean Medical Science, 2006, 21, 683. Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study. International Journal of Gynecological 1.2 Cancer, 2006, 16, 1112-1118. 230 Prognostic Factors and New Methods in Cervical Carcinoma., 2006, 11, 130-139. 1 Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by 1.2 radiotherapy. International Journal of Gynecological Cancer, 2006, 16, 623-630.

	Сітат	fion Report	
#	Article	IF	CITATIONS
232	Micrometastases detected by cytokeratin 19 expression in sentinel lymph nodes of patients with early-stage cervical cancer. International Journal of Gynecological Cancer, 2006, 16, 643-648.	1.2	50
233	Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study. International Journal of Gynecological Cancer, 2006, 16, 1112-1118.	1.2	25
234	What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case–control study. International Journal of Gynecological Cancer, 2006, 16, 1569-1573.	1.2	59
235	A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: Follow-up of a gynecologic oncology group study. International Journal of Radiation Oncology Biology Physics, 2006, 65, 169-176.	0.4	494
236	Influence of margin status and radiation on recurrence after radical hysterectomy in Stage IB cervical cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1501-1507.	0.4	41
238	Conservative surgery for early stage cervical carcinoma. Reviews in Gynaecological and Perinatal Practice, 2006, 6, 1-11.	0.3	Ο
239	Postoperative radiation therapy for carcinoma of the uterine cervix. Radiation Medicine, 2006, 24, 91-97.	0.8	18
240	Influence of quantity of lymph vascular space invasion on time to recurrence in women with early-stage squamous cancer of the cervix. Gynecologic Oncology, 2006, 100, 288-293.	0.6	47
241	Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecologic Oncology, 2006, 100, 591-595.	0.6	16
242	Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecologic Oncology, 2006, 101, 398-402.	0.6	19
243	ls intraoperative frozen section analysis of pelvic lymph nodes accurate after neoadjuvant chemotherapy in patients with cervical cancer?. Gynecologic Oncology, 2006, 103, 106-112.	0.6	23
244	Gynaecological cancer surgery. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 157-172.	1.4	2
245	Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix. Cancer, 2006, 107, 2932-2941.	2.0	20
247	Weak Expression of Focal Adhesion Kinase (pp125FAK) in Patients with Cervical Cancer Is Associated with Poor Disease Outcome. Clinical Cancer Research, 2006, 12, 2476-2483.	3.2	53
248	Antitumor Therapeutic Effects of E7 Subunit and DNA Vaccines in an Animal Cervical Cancer Model: Antitumor Efficacy of E7 Therapeutic Vaccines Is Dependent on Tumor Sizes, Vaccine Doses, and Vaccine Delivery Routes. DNA and Cell Biology, 2006, 25, 277-286.	0.9	21
249	Surgery Insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer. Nature Clinical Practice Oncology, 2007, 4, 353-361.	4.3	124
250	Tumor Volume and Uterine Body Invasion Assessed by MRI for Prediction of Outcome in Cervical Carcinoma Treated with Concurrent Chemotherapy and Radiotherapy. Japanese Journal of Clinical Oncology, 2007, 37, 858-866.	0.6	31
251	Role of Human Papillomavirus Genotype in Prognosis of Early-Stage Cervical Cancer Undergoing Primary Surgery. Journal of Clinical Oncology, 2007, 25, 3628-3634.	0.8	123

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
252	Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women. International Journal of Oncology, 2007, 31, 531.	1.4	5
253	Prognosis of Early Cervical Cancer (FIGO Stages IA2, IB, and IIA) in Northern Norway Predicted by Malignancy Grading Score and Objective Morphometric Image Analysis. International Journal of Gynecological Pathology, 2007, 26, 447-456.	0.9	16
256	Invasive Cervical Cancer. , 2007, , 55-124.		8
257	Clear Cell Adenocarcinoma of the Uterine Cervix. Taiwanese Journal of Obstetrics and Gynecology, 2007, 46, 453-455.	0.5	5
258	HPV16-E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse-transcription PCR. International Journal of Cancer, 2007, 120, 1842-1846.	2.3	32
259	The sentinel concept in patients with cervical cancer. Journal of Surgical Oncology, 2007, 96, 337-341.	0.8	22
260	Salvaging Locoregional Recurrence with Radiotherapy after Surgery in Early Cervical Cancer. Clinical Oncology, 2007, 19, 763-768.	0.6	23
261	Preoperative external beam radiotherapy and reduced dose brachytherapy for carcinoma of the cervix: survival and pathological response. Radiation Oncology, 2007, 2, 9.	1.2	3
262	Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables. International Journal of Gynecological Cancer, 2007, 17, 164-173.	1.2	12
263	Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. International Journal of Gynecological Cancer, 2007, 17, 813-820.	1.2	4
264	Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study. International Journal of Gynecological Cancer, 2007, 17, 833-842.	1.2	87
265	The value of prognostic factors for uterine cervical cancer patients treated with irradiation alone. BMC Cancer, 2007, 7, 234.	1.1	32
266	Isolated full-thickness cervical stromal invasion warrants post-hysterectomy pelvic radiotherapy in FIGO stages IB–IIA uterine cervical carcinoma. Gynecologic Oncology, 2007, 104, 152-157.	0.6	6
267	Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate–carboxymethylcellulose (HA–CMC) barrier: A cost-effectiveness analysis. Gynecologic Oncology, 2007, 104, 739-746.	0.6	32
268	The treatment of early stage cervical cancer: An assessment of pre-operative factors. Gynecologic Oncology, 2007, 104, 665-669.	0.6	1
269	Dilution of dye improves parametrial SLN detection in patients with cervical cancer. Gynecologic Oncology, 2007, 105, 329-334.	0.6	17
270	Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's) Tj ETQq0 C Gynecologic Oncology, 2007, 106, 132-141.) 0 rgBT /Ove 0.6	erlock 10 Tf 5 196
271	Treatment of ("bulkyâ€) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group. Gynecologic Oncology, 2007, 106, 362-369.	0.6	158

#	Article	IF	CITATIONS
272	Preoperative lymph-vascular space invasion is associated with nodal metastases in women with early-stage cervical cancer. Gynecologic Oncology, 2007, 106, 12-15.	0.6	29
273	Sentinel lymph node detection in early stage uterine cervix carcinoma: A systematic review. Gynecologic Oncology, 2007, 106, 604-613.	0.6	150
274	Early stage cervical cancer: Adjuvant treatment in negative lymph node cases. Gynecologic Oncology, 2007, 107, S170-S174.	0.6	59
275	The contribution of new imaging techniques in staging cervical cancer. Gynecologic Oncology, 2007, 107, S10-S12.	0.6	11
276	Do we need a new classification for radical hysterectomy? Insights in surgical anatomy and local tumor spread from human embryology. Gynecologic Oncology, 2007, 107, S106-S112.	0.6	25
277	Where to look for the sentinel lymph node in cervical cancer. American Journal of Obstetrics and Gynecology, 2007, 197, 678.e1-678.e7.	0.7	41
278	Clinical outcome following radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 723-727.	0.1	1
279	Clinical Value of Immunohistochemically Detected Lymphovascular Space Invasion in Early Stage Cervical Carcinoma. Annals of Surgical Oncology, 2008, 15, 2581-2588.	0.7	30
280	Pretreatment Staging of Cervical Cancer: Is Imaging Better Than Palpation?. Annals of Surgical Oncology, 2008, 15, 2856-2861.	0.7	48
281	Analysis of prognostic factors for 5 year survival in surgically treated patients with carcinoma cervix stages IB1, IB2 and IIA. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 42-47.	0.7	0
282	An individual prediction of the future (disease-free) survival of patients with a history of early-stage cervical cancer, multistate model. International Journal of Gynecological Cancer, 2008, 18, 432-438.	1.2	4
283	Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage IB–IIA cervical cancer. International Journal of Gynecological Cancer, 2008, 18, 1027-1031.	1.2	30
284	Treatment options in bulky stage IB cervical carcinoma. International Journal of Gynecological Cancer, 2008, 18, 1153-1162.	1.2	15
285	British HIV Association guidelines for HIVâ€associated malignancies 2008. HIV Medicine, 2008, 9, 336-388.	1.0	158
286	Pretreatment tumor diameter/volume and pelvic lymph node status assessed by magnetic resonance imaging for uterine cervical carcinoma treated with concurrent chemotherapy and radiotherapy. Journal of Obstetrics and Gynaecology Research, 2008, 34, 529-537.	0.6	10
287	Lymph node metastases, not human telomerase reverse transcriptase or p53 proteins, as the strongest prognostic factor for survival in early stage cervical cancer. Journal of Obstetrics and Gynaecology Research, 2008, 34, 1002-1009.	0.6	3
288	Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. European Journal of Cancer Care, 2008, 17, 174-181.	0.7	31
289	A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5Âyears. Gynecologic Oncology, 2008, 108, 106-111.	0.6	87

#	Article	IF	CITATIONS
290	Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B–2B cervical cancer. Gynecologic Oncology, 2008, 111, 444-448.	0.6	21
291	Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience. Seminars in Oncology, 2008, 35, 507-521.	0.8	19
292	Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix. Cancer Letters, 2008, 262, 183-189.	3.2	10
293	Comparison of biological behavior between early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 136, 215-223.	0.5	23
295	Sentinel Lymph Node Identification and Radical Hysterectomy with Lymphadenectomy in Early Stage Cervical Cancer: Laparoscopy Versus Laparotomy. Journal of Minimally Invasive Gynecology, 2008, 15, 531-537.	0.3	42
296	Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update. Annals of Oncology, 2008, 19, vii70-vii76.	0.6	9
297	A Combination of Serum Tumor Markers Identifies High-Risk Patients with Early-Stage Squamous Cervical Cancer. Tumor Biology, 2008, 29, 9-17.	0.8	20
298	Multicenter Validation Study of the Sentinel Lymph Node Concept in Cervical Cancer: AGO Study Group. Journal of Clinical Oncology, 2008, 26, 2943-2951.	0.8	265
299	Quality Control in Sentinel Lymph Node Biopsy in Cervical Cancer. Journal of Clinical Oncology, 2008, 26, 2930-2931.	0.8	16
300	Primary Management of Early Stage Cervical Cancer (IA1-IB) and Appropriate Selection of Adjuvant Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 47-52.	2.3	47
301	MR Imaging Findings of Uterine Cervical Carcinoma. Current Medical Imaging, 2008, 4, 83-95.	0.4	0
302	Extralesional Detection and Load of Human Papillomavirus DNA. Journal of Lower Genital Tract Disease, 2008, 12, 204-209.	0.9	4
303	Differing prognosis of cervical cancer patients with high risk of treatment failure after radical hysterectomy warrants trial treatment modification. Journal of Gynecologic Oncology, 2009, 20, 17.	1.0	6
304	Videolaparoscopic Radical Hysterectomy Approach: a Ten-Year Experience. Journal of the Society of Laparoendoscopic Surgeons, 2009, 13, 504-508.	0.5	5
305	Differing prognosis of cervical cancer patients with high risk of treatment failure after radical hysterectomy: To the editor. Journal of Gynecologic Oncology, 2009, 20, 132.	1.0	0
306	In reply. Journal of Gynecologic Oncology, 2009, 20, 133.	1.0	0
307	Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy. Journal of Gynecologic Oncology, 2009, 20, 227.	1.0	12
308	Sentinel lymph node examination for cancer of the uterine cervix. Journal of Clinical Pathology, 2009, 62, 1062-5.	1.0	15

#	Article	IF	CITATIONS
309	Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma, Cervical Cancer, and Endometrial Cancer. Oncologist, 2009, 14, 695-705.	1.9	36
310	SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. Gynecologic Oncology, 2009, 112, 119-125.	0.6	37
311	Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. Gynecologic Oncology, 2009, 112, 95-103.	0.6	50
312	Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 2009, 112, 583-589.	0.6	71
313	Validation of existing prognostic models in patients with early-stage cervical cancer. Gynecologic Oncology, 2009, 115, 277-284.	0.6	23
314	Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecologic Oncology, 2009, 115, 482-487.	0.6	44
315	How valid are current cervical cancer prognostic factors that are used to recommend adjunctive radiation therapy after radical surgery?. American Journal of Obstetrics and Gynecology, 2009, 201, 260.e1-260.e3.	0.7	2
316	Lymph node assessment in cervical cancer: Prognostic and therapeutic implications. Journal of Surgical Oncology, 2009, 99, 242-247.	0.8	71
317	Laparoscopic debulking of bulky lymph nodes in women with cervical cancer: indication and surgical outcomes. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 688-692.	1.1	13
318	Lymphovascular space involvement in early stage wellâ€differentiated endometrial cancer is associated with increased mortality. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 991-994.	1.1	46
319	Clinical Tumor Dimensions May Be Useful to Prevent Geographic Miss in Conventional Radiotherapy of Uterine Cervix Cancer—A Magnetic Resonance Imaging–Based Study. International Journal of Radiation Oncology Biology Physics, 2009, 74, 503-510.	0.4	7
320	Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancer. Ultrasound in Obstetrics and Gynecology, 2009, 34, 335-344.	0.9	76
321	Significance of nuclear hTra2â€beta1 expression in cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 216-221.	1.3	20
322	A validation study of new risk grouping criteria for postoperative treatment in stage IB cervical cancers without high-risk factors: Rethinking the Gynecologic Oncology Group criteria. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 147, 91-96.	0.5	11
324	Revised FIGO staging for carcinoma of the cervix. International Journal of Gynecology and Obstetrics, 2009, 105, 107-108.	1.0	582
325	PET and PET–CT imaging of gynecological malignancies: present role and future promise. Expert Review of Anticancer Therapy, 2009, 9, 75-96.	1.1	35
326	Prognostic Significance of Histology and Positive Lymph Node Involvement Following Radical Hysterectomy in Carcinoma of the Cervix. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 411-416.	0.6	90
327	Can Recurrence of Cervical Cancer Be Predicted by Human Papillomavirus DNA in Nodes or Plasma?. Journal of Lower Genital Tract Disease, 2009, 13, 102-106.	0.9	1

#	Article	IF	CITATIONS
328	Stage IA2 Cervical Carcinoma: How Much Treatment Is Enough?. International Journal of Gynecological Cancer, 2009, 19, 1620-1624.	1.2	32
329	Predictive Value of a Proposed Subclassification of Stages I and II Cervical Cancer Based on Clinical Tumor Diameter. International Journal of Gynecological Cancer, 2009, 19, 2-7.	1.2	32
331	Class II Radical Hysterectomy in Low-Risk IB Squamous Cell Carcinoma of Cervix: A Safe and Effective Option. International Journal of Gynecological Cancer, 2009, 19, 46-49.	1.2	28
332	Advanced adenoid cystic carcinoma of the cervix: a case report and review of the literature. Cases Journal, 2009, 2, 6634.	0.4	13
333	Stromal issues in cervical cancer: a review of the role and function of basement membrane, stroma, immune response and angiogenesis in cervical cancer development. European Journal of Cancer Prevention, 2010, 19, 204-215.	0.6	18
334	Locally advanced cervical cancer: what is the standard of care?. Current Opinion in Oncology, 2010, 22, 503-512.	1.1	33
335	Neoadjuvant Weekly Carboplatin and Paclitaxel Followed by Radical Hysterectomy for Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2010, 20, 611-616.	1.2	31
336	Results of Surgery After Concurrent Chemoradiotherapy in Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2010, 20, 268-275.	1.2	54
337	Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2010, 20, 164-172.	1.2	5
338	Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1467-1473.	3.3	49
340	Adenocarcinoma: A unique cervical cancer. Gynecologic Oncology, 2010, 116, 140-146.	0.6	224
341	Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 2010, 116, 452-458.	0.6	53
342	Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. Gynecologic Oncology, 2010, 117, 59-64.	0.6	85
343	Fertility-sparing options for early stage cervical cancer. Gynecologic Oncology, 2010, 117, 350-357.	0.6	106
344	Conservative surgery for early stage cervical cancer: Who should we offer it to?. Gynecologic Oncology, 2010, 119, 173-174.	0.6	1
345	Ultraâ€early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer. Cancer, 2010, 116, 903-912.	2.0	69
346	Should simple hysterectomy be added after chemoâ€radiation for stage IB2 and bulky IIA cervical carcinoma?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2010, 50, 289-293.	0.4	2
347	The impact of lymph node density on survival of cervical cancer patients. British Journal of Cancer, 2010, 103, 613-616.	2.9	42

#	Article	IF	CITATIONS
348	Feasibility and Outcome of Concurrent Chemoradiotherapy for Recurrent Cervical Carcinoma after Initial Surgery. Tumori, 2010, 96, 553-559.	0.6	14
349	Lymph Node Staging by Positron Emission Tomography in Cervical Cancer: Relationship to Prognosis. Journal of Clinical Oncology, 2010, 28, 2108-2113.	0.8	262
351	Early-stage cervical cancer: is surgery better than radiotherapy?. Expert Review of Anticancer Therapy, 2010, 10, 451-460.	1.1	28
352	Neoplastic Lesions of the Cervix. Surgical Pathology Clinics, 2011, 4, 17-86.	0.7	2
353	Impact of MRI in the management and staging of cancer of the uterine cervix. Acta Oncológica, 2011, 50, 420-426.	0.8	35
354	Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 155, 188-192.	0.5	34
355	Impact of Epidermal Growth Factor Receptor Expression on Disease-Free Survival and Rate of Pelvic Relapse in Patients With Advanced Cancer of the Cervix Treated With Chemoradiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 395-400.	0.6	21
356	Stage IIA1 Versus Stage IIA2 Cervical Cancer: Does the New Staging Criteria Predict Survival?. International Journal of Gynecological Cancer, 2011, 21, 711-716.	1.2	13
357	Recent Developments in Defining Microinvasive and Early Invasive Carcinoma of the Uterine Cervix. Journal of Lower Genital Tract Disease, 2011, 15, 146-157.	0.9	26
358	Surgical Staging for Cervical Cancer. Current Women's Health Reviews, 2011, 7, 69-74.	0.1	0
359	An Occult Invasive Cervical Cancer Found After a Simple Hysterectomy: A 10-Year Experience in a Single Institution. International Journal of Gynecological Cancer, 2011, 21, 1646-1653.	1.2	5
360	Parametrial Involvement in FIGO Stage IB1 Cervical Carcinoma: Diagnostic Impact of Tumor Diameter in Preoperative Magnetic Resonance Imaging. International Journal of Gynecological Cancer, 2011, 21, 349-354.	1.2	48
361	Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases. Gynecologic Oncology, 2011, 120, 94-100.	0.6	29
362	Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecologic Oncology, 2011, 120, 270-274.	0.6	121
363	HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB–IIA cervical cancer undergoing radical hysterectomy. Gynecologic Oncology, 2011, 121, 546-550.	0.6	30
364	Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgery. Gynecologic Oncology, 2011, 121, 551-557.	0.6	24
365	Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecologic Oncology, 2011, 122, 25-32.	0.6	80
366	Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecologic Oncology, 2011, 122, 275-280.	0.6	146

#	Article	IF	CITATIONS
367	Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB–IIA1). Gynecologic Oncology, 2011, 122, 484-490.	0.6	71
368	Tailoring adjuvant radiotherapy for stage IB–IIA node negative cervical carcinoma after radical hysterectomy and pelvic lymph node dissection using the GOG score. Gynecologic Oncology, 2011, 123, 225-229.	0.6	14
369	Surgical treatment of lymph node metastases in stage IB cervical cancer. The laterally extended parametrectomy (LEP) procedure: Experience with a 5year follow-up. Gynecologic Oncology, 2011, 123, 337-341.	0.6	14
370	Trachelectomy for cancer of the cervix: Dargent's operation. Vaginal hysterectomy for early cancer of the cervix stage IA1 and CIN III. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 217-225.	1.4	7
371	Earlyâ€stage cervical cancer: agreement between ultrasound and histopathological findings with regard to tumor size and extent of local disease. Ultrasound in Obstetrics and Gynecology, 2011, 38, 707-715.	0.9	29
373	Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer, 2011, 11, 12.	1.1	52
374	Class II radical hysterectomy for stage l–IIA cervix cancer: Prognostic factors associated to recurrence and survival in a northeast Brazil experience. Journal of Surgical Oncology, 2011, 104, 255-259.	0.8	9
375	Therapeutic role of lymphadenectomy for cervical cancer. Cancer, 2011, 117, 310-317.	2.0	51
376	Prognostic model for survival in patients with early stage cervical cancer. Cancer, 2011, 117, 768-776.	2.0	129
377	Is Adjuvant Chemoradiotherapy Overtreatment in Cervical Cancer Patients With Intermediate Risk Factors?. International Journal of Radiation Oncology Biology Physics, 2011, 79, 794-799.	0.4	54
378	Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer. Chemotherapy Research and Practice, 2011, 2011, 1-10.	1.6	15
379	Whole Slide Quantification of Stromal Lymphatic Vessel Distribution and Peritumoral Lymphatic Vessel Density in Early Invasive Cervical Cancer: A Method Description. ISRN Obstetrics & Gynecology, 2011, 2011, 1-7.	1.2	22
380	Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer. Annals of Oncology, 2011, 22, 59-67.	0.6	62
381	Positron Lymphography: Multimodal, High-Resolution, Dynamic Mapping and Resection of Lymph Nodes After Intradermal Injection of ¹⁸ F-FDG. Journal of Nuclear Medicine, 2012, 53, 1438-1445.	2.8	55
382	Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study. Annals of Oncology, 2012, 23, 903-911.	0.6	217
383	Nomogram prediction for overall survival of patients diagnosed with cervical cancer. British Journal of Cancer, 2012, 107, 918-924.	2.9	79
384	What is your diagnosis?. Journal of the Turkish German Gynecology Association, 2012, 13, 221-222.	0.2	0
385	Validity of Laparoscopic Staging to Avoid Adjuvant Chemoradiation following Radical Surgery in Patients with Early Cervical Cancer. Oncology, 2012, 83, 346-353.	0.9	32

#	Article	IF	CITATIONS
386	A Review of Surgical Options to Preserve Fertility in the Treatment of Early Cervical Cancer. Current Women's Health Reviews, 2012, 8, 219-230.	0.1	1
387	Comparison of the Prognoses of FIGO Stage I to Stage II Adenosquamous Carcinoma and Adenocarcinoma of the Uterine Cervix Treated With Radical Hysterectomy. International Journal of Gynecological Cancer, 2012, 22, 1389-1397.	1.2	25
388	A Prospective Single-Center Study of Sentinel Lymph Node Detection in Cervical Carcinoma: Is There a Place in Clinical Practice?. International Journal of Gynecological Cancer, 2012, 22, 1044-1049.	1.2	23
389	Analysis of Prognostic Variables, Development of Predictive Models, and Stratification of Risk Groups in Surgically Treated FIGO Early-Stage (IA–IIA) Carcinoma Cervix. International Journal of Gynecological Cancer, 2012, 22, 115-122.	1.2	19
390	The Prognostic Significance of Multiple Pelvic Node Metastases in Cervical Cancer Patients Treated With Radical Hysterectomy Plus Adjuvant Chemoradiotherapy. International Journal of Gynecological Cancer, 2012, 22, 490-497.	1.2	26
391	18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecologic Oncology, 2012, 127, 131-135.	0.6	74
392	Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 2012, 126, 317-318.	0.6	7
393	Does a uterine manipulator affect cervical cancer pathology or identification of lymphovascular space involvement?. Gynecologic Oncology, 2012, 127, 98-101.	0.6	33
394	Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecologic Oncology, 2012, 127, 290-296.	0.6	83
395	Relationship between lymph node metastases and histopathological parameters in carcinoma cervix: A multivariate analysis. Journal of Obstetrics and Gynaecology, 2012, 32, 78-80.	0.4	8
396	Invasive Cervical Cancer. , 2012, , 51-119.e13.		15
397	3D Radiation Therapy or Intensity-Modulated Radiotherapy for Recurrent and Metastatic Cervical Cancer: The Shanghai Cancer Hospital Experience. PLoS ONE, 2012, 7, e40299.	1.1	8
398	Detection of Sentinel Lymph Nodes in Gynecologic Tumours by Planar Scintigraphy and SPECT/CT. Molecular Imaging and Radionuclide Therapy, 2012, 21, 47-55.	0.3	36
399	The role of imaging in the management of non-metastatic cervical cancer. Medical Oncology, 2012, 29, 3389-3393.	1.2	3
400	Comparison of Laparoscopic-Assisted Radical Vaginal Hysterectomy and Laparoscopic Radical Hysterectomy in the Treatment of Cervical Cancer. Annals of Surgical Oncology, 2012, 19, 3839-3848.	0.7	31
401	Role of Sentinel Lymph Node Biopsy in Early Cervical Cancer. Indian Journal of Surgical Oncology, 2012, 3, 317-320.	0.3	4
402	Detection of sentinel lymph nodes by SPECT/CT and planar scintigraphy: The influence of age, gender and BMI. Journal of Biomedical Graphics and Computing, 2012, 2, .	0.2	2
403	Surgicalâ€pathologic risk factors of pelvic lymph node metastasis in stage Ib1â€IIb cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 802-809.	1.3	24

#	Article	IF	CITATIONS
404	Biological Predictors of Cervical Cancer Response to Radiation Therapy. Seminars in Radiation Oncology, 2012, 22, 143-150.	1.0	31
405	ls imaging relevant for treatment choice in early stage cervical uterine cancer?. Surgical Oncology, 2012, 21, e1-e6.	0.8	8
406	20year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: Impact of treatment period and concurrent chemotherapy. Gynecologic Oncology, 2012, 124, 63-67.	0.6	37
407	ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer. Gynecologic Oncology, 2012, 125, 256-262.	0.6	20
408	Evaluation of cervical conization as a definitive treatment for microinvasive cervical carcinoma and cervical intraepithelial neoplasia grade 3. Archives of Gynecology and Obstetrics, 2012, 285, 453-457.	0.8	3
409	The effects of age on treatment and outcomes in women with stages IB1–IIB cervical cancer. Journal of Geriatric Oncology, 2013, 4, 374-381.	0.5	4
411	The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer. Gynecologic Oncology, 2013, 128, 44-48.	0.6	37
412	Gynecologic Cancers. , 2013, , 591-620.		0
413	Impact of tumor size on survival in cancer of the cervix and validation of stage IIA1 and IIA2 subdivisions. Gynecologic Oncology, 2013, 129, 517-521.	0.6	62
414	Survival analysis of Stage IIA1 and IIA2 cervical cancer patients. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 33-38.	0.5	13
415	Problematic issues in the staging of endometrial, cervical and vulval carcinomas. Histopathology, 2013, 62, 176-202.	1.6	43
416	Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Human Pathology, 2013, 44, 1365-1374.	1.1	46
417	Relationship Between Imaging Biomarkers of Stage I Cervical Cancer and Poor-Prognosis Histologic Features: Quantitative Histogram Analysis of Diffusion-Weighted MR Images. American Journal of Roentgenology, 2013, 200, 314-320.	1.0	130
418	Early-stage cervical cancer: Tumor delineation by magnetic resonance imaging and ultrasound — A European multicenter trial. Gynecologic Oncology, 2013, 128, 449-453.	0.6	115
419	Primary Surgical Management With Tailored Adjuvant Radiation for Stage IB2 Cervical Cancer. Obstetrics and Gynecology, 2013, 121, 765-772.	1.2	10
420	Radical Surgery With Individualized Postoperative Radiation for Stage IB Cervical Cancer: Oncologic Outcomes and Severe Complications. International Journal of Gynecological Cancer, 2013, 23, 553-558.	1.2	8
421	Significance of the Absolute Number and Ratio of Metastatic Lymph Nodes in Predicting Postoperative Survival for the International Federation of Gynecology and Obstetrics Stage IA2 to IIA Cervical Cancer. International Journal of Gynecological Cancer, 2013, 23, 157-163.	1.2	33
422	Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals. Geburtshilfe Und Frauenheilkunde, 2013, 73, 227-238.	0.8	14

#	Article	IF	CITATIONS
423	Gynecologic Biopsy for Molecular Profiling: A Review for the Interventional Radiologist. Seminars in Interventional Radiology, 2013, 30, 417-424.	0.3	4
424	Potential Molecular Mechanisms for Improved Prognosis and Outcome with Neoadjuvant Chemotherapy Prior to Laparoscopical Radical Hysterectomy for Patients with Cervical Cancer. Cellular Physiology and Biochemistry, 2013, 32, 1528-1540.	1.1	16
425	Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies. Therapeutic Advances in Medical Oncology, 2013, 5, 211-219.	1.4	33
426	Prognostic Significance of Perineural Invasion in Cervical Cancer. International Journal of Gynecological Pathology, 2013, 32, 228-233.	0.9	27
427	Identification of the deleted in split hand/split foot 1 protein as a novel biomarker for human cervical cancer. Carcinogenesis, 2013, 34, 68-78.	1.3	11
428	Utility of risk-weighted surgical–pathological factors in early-stage cervical cancer. British Journal of Cancer, 2013, 108, 1348-1357.	2.9	17
429	Report 89. Journal of the ICRU, 2013, 13, NP.3-NP.	6.0	30
430	P27 as a Prognostic Factor of Early Cervical Carcinoma. International Journal of Gynecological Cancer, 2013, 23, 164-169.	1.2	7
431	Three-Dimensional Transvaginal Ultrasonography for Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2013, 23, 1459-1464.	1.2	21
432	Analysis of a Continuous Series of 34 Young Patients With Early-Stage Cervical Cancer Selected for a Vaginal Radical Trachelectomy. International Journal of Gynecological Cancer, 2013, 23, 331-336.	1.2	19
434	Impact of the Addition of Concurrent Chemotherapy to Pelvic Radiotherapy in Surgically Treated Stage IB1-IIB Cervical Cancer Patients With Intermediate-Risk or High-Risk Factors: A 13-Year Experience. International Journal of Gynecological Cancer, 2013, 23, 567-575.	1.2	50
435	A Retrospective Review of Patients With Stage IB2 Cervical Cancer Treated With Radical Radiation Versus Radical Surgery as a Primary Modality. International Journal of Gynecological Cancer, 2013, 23, 1287-1294.	1.2	11
436	Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer. Obstetrics and Gynecology Science, 2013, 56, 15.	0.6	20
437	Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer. Clinics, 2013, 68, 809-814.	0.6	21
438	Maintenance of ovarian function in end-of-life cervical cancer patient following primary surgico-radiotherapy and ovarian transposition. Journal of Gynecologic Oncology, 2013, 24, 204.	1.0	2
439	PET-MRI Based Molecular Imaging as a Response Marker in Cervical Cancer: A Systematic Review. Current Molecular Imaging, 2013, 2, 66-76.	0.7	1
440	Defining the concept of locally advanced squamous cell carcinoma of the vulva: a new perspective based on standardization of criteria and current evidence. Journal of Gynecologic Oncology, 2014, 25, 272.	1.0	10
441	The Expression of Ribonucleotide Reductase M2 in the Carcinogenesis of Uterine Cervix and Its Relationship with Clinicopathological Characteristics and Prognosis of Cancer Patients. PLoS ONE, 2014, 9, e91644.	1.1	19

#	Article	IF	CITATIONS
444	Improved computer-assisted analysis of the global lymphatic network in human cervical tissues. Modern Pathology, 2014, 27, 887-898.	2.9	20
445	Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study. British Journal of Cancer, 2014, 110, 278-285.	2.9	75
446	Management of Human Papillomavirus-Related Gynecological Malignancies. Current Problems in Dermatology, 2014, 45, 216-224.	0.8	2
447	The Role of Ultrasound in the Assessment of Uterine Cervical Cancer. Journal of Obstetrics and Gynecology of India, 2014, 64, 311-316.	0.3	23
448	Longâ€ŧerm outcomes after fertilityâ€sparing laparoscopic radical trachelectomy in young women with earlyâ€stage cervical cancer: An Asan Gynecologic Cancer Group (AGCG) study. Journal of Surgical Oncology, 2014, 110, 252-257.	0.8	70
449	Nerve-Sparing Radical Abdominal Trachelectomy Versus Nerve-Sparing Radical Hysterectomy in Early-Stage (FIGO IA2-IB) Cervical Cancer: A Comparative Study on Feasibility and Outcome. International Journal of Gynecological Cancer, 2014, 24, 735-743.	1.2	35
450	Value and Advantages of Preoperative Sentinel Lymph Node Imaging With SPECT/CT in Cervical Cancer. International Journal of Gynecological Cancer, 2014, 24, 295-302.	1.2	31
451	The Surgical Management of Cervical Cancer. Obstetrical and Gynecological Survey, 2014, 69, 426-441.	0.2	25
452	Prognostic implication of retrocrural lymph node involvement revealed by 18F-FDG PET/CT in patients with uterine cervical cancer. Nuclear Medicine Communications, 2014, 35, 268-275.	0.5	8
453	Neoadjuvant intra-arterial chemotherapy followed by total laparoscopic radical trachelectomy in stage IB1 cervical cancer. Fertility and Sterility, 2014, 101, 812-817.	0.5	20
454	Postoperative outcomes of MR-invisible stage IB1 cervical cancer. American Journal of Obstetrics and Gynecology, 2014, 211, 168.e1-168.e7.	0.7	16
455	Patterns of care in patients with cervical cancer 2012. Strahlentherapie Und Onkologie, 2014, 190, 34-40.	1.0	18
456	Application of machine learning to predict the recurrence-proneness for cervical cancer. Neural Computing and Applications, 2014, 24, 1311-1316.	3.2	78
457	Tumor-free distance from outermost layer of cervix is of prognostic value in surgically treated cervical cancer patients: a multicenter study. Archives of Gynecology and Obstetrics, 2014, 289, 1331-1335.	0.8	5
458	Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecologic Oncology, 2014, 135, 213-216.	0.6	82
459	Analysis of the effect of adjuvant radiotherapy on outcome and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors. Gynecologic Oncology, 2014, 133, 61-62.	0.6	1
460	Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 674-681.	3.3	23
461	Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix. Gynecologic Oncology, 2014, 132, 474-482.	0.6	12

#	Article	IF	CITATIONS
462	Post-operative radiotherapy in patients with early stage cervical cancer. Gynecologic Oncology, 2014, 134, 52-59.	0.6	20
463	Tumor–stroma ratio is an independent predictor for survival in early cervical carcinoma. Gynecologic Oncology, 2014, 132, 81-86.	0.6	61
464	Pattern of Cancer Recurrence in 320 Patients After Radical Vaginal Trachelectomy. International Journal of Gynecological Cancer, 2014, 24, 130-134.	1.2	46
465	Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. The Cochrane Library, 2015, , CD010260.	1.5	62
466	Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of Survival. International Journal of Gynecological Pathology, 2015, 34, 379-384.	0.9	20
467	Preoperative prediction of lymph node metastasis and deep stromal invasion in women with invasive cervical cancer: prospective multicenter study using <scp>2D</scp> and <scp>3D</scp> ultrasound. Ultrasound in Obstetrics and Gynecology, 2015, 45, 470-475.	0.9	22
468	Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer. International Journal of Gynecological Cancer, 2015, 25, 1461-1467.	1.2	18
469	Agreement of twoâ€dimensional and threeâ€dimensional transvaginal ultrasound with magnetic resonance imaging in assessment of parametrial infiltration in cervical cancer. Ultrasound in Obstetrics and Gynecology, 2015, 45, 459-469.	0.9	19
470	Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery. Journal of Gynecologic Oncology, 2015, 26, 111.	1.0	25
472	Prognostic analysis of uterine cervical cancer treated with postoperative radiotherapy: importance of positive or close parametrial resection margin. Radiation Oncology Journal, 2015, 33, 109.	0.7	24
473	Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors. Journal of Gynecologic Oncology, 2015, 26, 3.	1.0	20
474	Cervical Cancer Stem Cells and Their Association with Human Papillomavirus: Are They Ready as Anticancer Targets?. , 2015, , 377-399.		2
475	Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. Journal of Clinical Oncology, 2015, 33, 2136-2142.	0.8	135
476	Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in in in intermediate-risk cervical cancer patients after radical hysterectomy. BMC Cancer, 2015, 15, 353.	1.1	15
477	Pathological Risk Factors and Outcomes in Women With Stage IB2 Cervical Cancer Treated With Primary Radical Surgery Versus Chemoradiotherapy. International Journal of Gynecological Cancer, 2015, 25, 1476-1483.	1.2	11
478	Approach and Management of Cervical Cancer. , 2015, , 435-486.		0
480	Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecologic Oncology, 2015, 136, 48-53.	0.6	79
481	Radiation Therapy for Pelvic Malignancy and its Consequences. , 2015, , .		3

#	Article	IF	Citations
482	Multi-Targeted Approach to Treatment of Cancer. , 2015, , .		1
483	Staging for cervix cancer: Role of radiology, surgery and clinical assessment. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 833-844.	1.4	17
484	Review of Neoadjuvant Chemotherapy and Trachelectomy: Which Cervical Cancer Patients Would Be Suitable for Neoadjuvant Chemotherapy Followed by Fertility-Sparing Surgery?. Current Oncology Reports, 2015, 17, 446.	1.8	33
485	Can a Sentinel Node Mapping Algorithm Detect All Positive Lymph Nodes in Cervical Cancer?. Annals of Surgical Oncology, 2015, 22, 1564-1569.	0.7	11
486	Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review. European Journal of Surgical Oncology, 2015, 41, 975-985.	0.5	70
487	Fludeoxyglucose F 18 PET–Computed Tomography. PET Clinics, 2015, 10, 395-409.	1.5	6
488	When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer. Annals of Surgical Oncology, 2015, 22, 944-951.	0.7	13
489	Three-Dimensional Transvaginal Tomographic Ultrasound Imaging for Cervical Cancer Staging. Ultrasound in Medicine and Biology, 2015, 41, 2303-2309.	0.7	6
490	ls quantification of lymphovascular space invasion useful in stage 1B2 cervical carcinomas?. Journal of Obstetrics and Gynaecology, 2015, 35, 377-381.	0.4	2
491	Satellite lymphovascular space invasion: An independent risk factor in early stage cervical cancer. Gynecologic Oncology, 2015, 138, 579-584.	0.6	30
492	Postoperative Chemoradiation Therapy in High-Risk Cervical Cancer: Re-evaluating the Findings of Gynecologic Oncology Group Study 109 in a Large, Population-Based Cohort. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1032-1044.	0.4	26
493	Gynecologic Oncology. , 2015, , .		2
494	"Drop Recurrence" External Genitalia Recurrence in Carcinoma Cervix after Previous Surgery. Archives in Cancer Research, 2016, 4, .	0.3	0
495	Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy. OncoTargets and Therapy, 2016, 9, 3171.	1.0	4
496	Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy in early-stage cervical cancer patients with intermediate risk factors. OncoTargets and Therapy, 2016, Volume 9, 7331-7335.	1.0	7
497	The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation. Obstetrics and Gynecology Science, 2016, 59, 184.	0.6	5
498	Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study. Oncotarget, 2016, 7, 70969-70978.	0.8	16
499	Role of monocyte and lymphocyte counts in prognosis of cervical cancer. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2016, , 2243-2249.	0.0	1

#	Article	IF	CITATIONS
500	NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer. International Journal of Molecular Sciences, 2016, 17, 1694.	1.8	17
501	Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study). World Journal of Surgical Oncology, 2016, 14, 173.	0.8	28
502	High-Grade Tumor Budding Stratifies Early-Stage Cervical Cancer with Recurrence Risk. PLoS ONE, 2016, 11, e0166311.	1.1	25
503	The long noncoding RNA <i>HOXA11 antisense</i> induces tumor progression and stemness maintenance in cervical cancer. Oncotarget, 2016, 7, 83001-83016.	0.8	78
504	Management of Early-Stage and Locally Advanced Cervical Cancer. , 2016, , 1-9.		0
505	Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative isolated deep stromal invasion: a retrospective study. BMC Cancer, 2016, 16, 403.	1.1	12
506	Evaluation of Clinical and Pathologic Risk Factors May Reduce the Rate of Multimodality Treatment of Early Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 37-42.	0.6	11
507	Identification and Rating of Gynecologic Oncology Applications Using the APPLICATIONS Scoring System. Telemedicine Journal and E-Health, 2016, 22, 1001-1007.	1.6	7
508	Optimal pathological response indicated better long-term outcome among patients with stage IB2 to IIB cervical cancer submitted to neoadjuvant chemotherapy. Scientific Reports, 2016, 6, 28278.	1.6	15
509	Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. Journal of Oncology Practice, 2016, 12, 693-696.	2.5	19
510	Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer. Oncology Research and Treatment, 2016, 39, 522-524.	0.8	14
511	Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology, 2016, 2, 311-340.	0.5	127
512	Threeâ€Ðimensional Transvaginal Sonography and Magnetic Resonance Imaging for Local Staging of Cervical Cancer. Journal of Ultrasound in Medicine, 2016, 35, 867-873.	0.8	13
513	The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer. Annals of Surgical Oncology, 2016, 23, 2953-2958.	0.7	24
514	Beyond sentinel node algorithm. Toward a more tailored surgery for cervical cancer patients. Cancer Medicine, 2016, 5, 1725-1730.	1.3	22
515	Incontinence, Voiding Dysfunction, and Other Urologic Complications After Radiotherapy for Gynecologic Malignancies. Current Bladder Dysfunction Reports, 2016, 11, 88-97.	0.2	7
516	Splenic Metastasis from Cancer of Uterine Cervix—a Rare Case. Indian Journal of Surgical Oncology, 2016, 7, 479-483.	0.3	4
518	Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study. Gynecologic Oncology, 2016, 143, 539-544.	0.6	13

#	Article	IF	CITATIONS
519	Long-Term Oncological Outcomes After Laparoscopic Versus Abdominal Radical Hysterectomy in Stage IA2 to IIA2 Cervical Cancer: A Matched Cohort Study. International Journal of Gynecological Cancer, 2016, 26, 1264-1273.	1.2	64
521	Factors Associated with Increased HPV Vaccine Use in Ruralâ€Frontier U.S. States. Public Health Nursing, 2016, 33, 283-294.	0.7	19
522	Prognostic significance of positive lymph node number in early cervical cancer. Molecular and Clinical Oncology, 2016, 4, 1052-1056.	0.4	13
523	Endometrial and cervical cancer patients with multiple sentinel lymph nodes at laparoscopic ICG mapping: How many are enough?. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1831-1836.	1.2	29
524	Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. Surgical Oncology, 2016, 25, 229-235.	0.8	29
525	Unusual Metastasis from Carcinoma Cervix. Journal of Obstetrics and Gynecology of India, 2016, 66, 358-362.	0.3	17
526	Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncology, The, 2016, 17, e240-e253.	5.1	206
527	CPE overexpression is correlated with pelvic lymph node metastasis and poor prognosis in patients with early-stage cervical cancer. Archives of Gynecology and Obstetrics, 2016, 294, 333-342.	0.8	11
528	Stage <scp>IB</scp> cervix cancer with nodal involvement treated with primary surgery or primary radiotherapy: Patterns of failure and outcomes in a contemporary population. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 274-282.	0.9	9
529	Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study. International Journal of Clinical Oncology, 2016, 21, 735-740.	1.0	7
530	Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence. International Journal of Gynecology and Obstetrics, 2016, 133, 69-75.	1.0	41
531	Nerve Sparing Radical Hysterectomy: An Important Tool for the Gynecologic Oncologist. Indian Journal of Gynecologic Oncology, 2016, 14, 1.	0.1	0
533	Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie, 2016, 121, 298-311.	1.3	50
534	Management of cervical cancer during pregnancy. Journal of Obstetrics and Gynaecology, 2016, 36, 366-371.	0.4	8
535	Robotic retroperitoneal lymph node dissection in gynaecological neoplasms: comparison of extraperitoneal and transperitoneal lymphadenectomy. Archives of Gynecology and Obstetrics, 2016, 293, 11-28.	0.8	9
536	Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 241-249.	0.6	5
537	Costâ€effectiveness of sentinel node biopsy and pathological ultrastaging in patients with earlyâ€stage cervical cancer. Cancer, 2017, 123, 1751-1759.	2.0	37
538	Update on radiotherapy in gynaecological malignancies. The Obstetrician and Gynaecologist, 2017, 19, 29-36.	0.2	5

#	Article	IF	CITATIONS
539	A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection. Gynecologic Oncology, 2017, 144, 536-540.	0.6	26
540	Significance of uterine corpus tumor invasion in early-stage cervical cancer. European Journal of Surgical Oncology, 2017, 43, 725-734.	0.5	29
541	The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage l–II cervical cancer: A review. Journal of Obstetrics and Gynaecology Research, 2017, 43, 617-626.	0.6	36
543	ADAR1 overexpression is associated with cervical cancer progression and angiogenesis. Diagnostic Pathology, 2017, 12, 12.	0.9	36
544	Preoperatively Assessable Clinical and Pathological Risk Factors for Parametrial Involvement in Surgically Treated FIGO Stage IB–IIA Cervical Cancer. International Journal of Gynecological Cancer, 2017, 27, 1722-1728.	1.2	23
545	Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery. American Journal of Obstetrics and Gynecology, 2017, 217, 332.e1-332.e6.	0.7	22
546	Comparison of adjuvant therapy for nodeâ€positive clinical stage IBâ€IIB cervical cancer: Systemic chemotherapy <i>versus</i> pelvic irradiation. International Journal of Cancer, 2017, 141, 1042-1051.	2.3	59
547	Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management. Abdominal Radiology, 2017, 42, 2488-2512.	1.0	30
548	Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1862-1869.	3.3	19
550	Adjuvant Chemoradiation Therapy for Cervical Cancer and Effect of Timing and Duration on Treatment Outcome. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1132-1141.	0.4	20
551	Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis. International Journal of Gynecological Cancer, 2017, 27, 1935-1942.	1.2	22
552	Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 659-667.	0.3	10
553	Factors Predicting Pelvic Lymph Node Metastasis, Relapse, and Disease Outcome in Pattern C Endocervical Adenocarcinomas. International Journal of Gynecological Pathology, 2017, 36, 476-485.	0.9	31
554	Prognostic Significance of the Standardized Uptake Value of Pretherapeutic 18F-Labeled 2-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2017, 27, 530-536.	1.2	1
555	Would Lipophilic Statin Therapy as a Prognostic Factor Improve Survival in Patients With Uterine Cervical Cancer?. International Journal of Gynecological Cancer, 2017, 27, 1431-1437.	1.2	6
556	The combination of preoperative PET/CT and sentinel lymph node biopsy in the surgical management of early-stage cervical cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2275-2281.	1.2	14
557	Early Cervical Cancer: Current Dilemmas of Staging and Surgery. Current Oncology Reports, 2017, 19, 51.	1.8	26
558	¹ H MR spectroscopy in cervical carcinoma using external phase array body coil at 3.0 Tesla: Prediction of poor prognostic human papillomavirus genotypes. Journal of Magnetic Resonance Imaging, 2017, 45, 899-907.	1.9	10

#	Article	IF	CITATIONS
559	The detection of sentinel lymph nodes in laparoscopic surgery for uterine cervical cancer using 99m-technetium-tin colloid, indocyanine green, and blue dye. Journal of Gynecologic Oncology, 2017, 28, e13.	1.0	28
560	Randomized study between radical surgery and radiotherapy for the treatment of stage IB–IIA cervical cancer: 20-year update. Journal of Gynecologic Oncology, 2017, 28, e34.	1.0	113
561	Prediction of 5–year overall survival in cervical cancer patients treated with radical hysterectomy using computational intelligence methods. BMC Cancer, 2017, 17, 840.	1.1	44
562	Comparison of the efficacy among multiple chemotherapeutic interventions combined with radiation therapy for patients with cervix cancer after surgery: A network meta-analysis. Oncotarget, 2017, 8, 49515-49533.	0.8	8
563	Barriers and Challenges to Treatment Alternatives for Early-Stage Cervical Cancer in Lower-Resource Settings. Journal of Global Oncology, 2017, 3, 572-582.	0.5	22
564	The impact of malnutrition on survival in patients with gynecologic cancer undergoing chemotherapy. Journal of Nutrition and Health, 2017, 50, 595.	0.2	0
565	Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study. World Journal of Surgical Oncology, 2018, 16, 18.	0.8	29
566	Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study. International Journal of Clinical Oncology, 2018, 23, 715-725.	1.0	3
567	PET/MR Imaging: Current and Emerging Applications. , 2018, , .		4
568	Which is better for predicting pelvic lymph node metastases in patients with cervical cancer. Medicine (United States), 2018, 97, e0410.	0.4	11
569	Towards developing a meaningful grading system for cervical squamous cell carcinoma. Journal of Pathology: Clinical Research, 2018, 4, 81-85.	1.3	19
570	Female Pelvis. , 2018, , 63-81.		0
571	Surgical Treatment of Early-Stage Cervical Cancer: A Multi-Institution Experience in 2124 Cases in The Netherlands Over a 30-Year Period. International Journal of Gynecological Cancer, 2018, 28, 757-763.	1.2	39
572	Invasive Cervical Cancer. , 2018, , 38-104.e15.		2
573	Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology, 2018, 37, 205-228.	0.9	44
574	Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy. Frontiers in Oncology, 2018, 8, 546.	1.3	17
575	Vaginal cuff length during radical hysterectomy is a prognostic factor for stage IB-IIA cervical cancer: a retrospective study. Cancer Management and Research, 2018, Volume 10, 5927-5935.	0.9	6
576	Expression levels of the long noncoding RNA steroid receptor activator promote cell proliferation and invasion and predict patient prognosis in human cervical cancer. Oncology Letters, 2018, 16, 5410-5418.	0.8	8

		CITATION REPORT		
#	Article		IF	CITATIONS
577	Cancer of the cervix uteri. International Journal of Gynecology and Obstetrics, 2018, 1	43, 22-36.	1.0	746
578	A retrospective study of stage IB node-negative cervical cancer treated with adjuvant r standard pelvic versus central small pelvic fields. Southern African Journal of Gynaecolo Oncology, 2018, 10, 11-15.	radiation with ogical	0.3	1
579	Surgery in Cervical Cancer. New England Journal of Medicine, 2018, 379, 1955-1957.		13.9	32
580	Downregulation of Krïį¼2ppelâ€ʻlike factor 1 inhibits the metastasis and invasion of ce Molecular Medicine Reports, 2018, 18, 3932-3940.	rvical cancer cells.	1.1	7
581	The LACC Trial: Has Minimally Invasive Surgery for Early-Stage Cervical Cancer Been De Punch?. International Journal of Gynecological Cancer, 2018, 28, 1248-1250.	alt a Knockout	1.2	31
582	Twenty-first century cervical cancer management: A historical perspective of the gyned oncology group/NRG oncology over the past twenty years. Gynecologic Oncology, 202	cologic 18, 150, 391-397.	0.6	39
583	Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from inc green combined with technetiumâ€99mâ€nanocolloid. Lasers in Surgery and Medicine	docyanine 2, 2018, 50, 994-1001.	1.1	16
584	Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IE cancer patients. Journal of Gynecologic Oncology, 2018, 29, e5.	8–IIA cervical	1.0	7
585	Treatment outcomes of high-dose-rate intracavitary brachytherapy for cervical cancer: of Ir-192 versus Co-60 sources. Journal of Gynecologic Oncology, 2018, 29, e86.	a comparison	1.0	22
586	Perineural invasion in early-stage cervical cancer and its relevance following surgery. O Letters, 2018, 15, 6555-6561.	ncology	0.8	21
587	Cisplatin concurrent chemoradiotherapy vs adjuvant radiation in stage IB/IIA cervical c intermediate risk factors, treated with radical surgery: a retrospective study. OncoTarg Therapy, 2018, Volume 11, 1149-1155.	ancer with gets and	1.0	10
588	Lymph nodes metastasis in cervical cancer: Incidences, risk factors, consequences and evaluations. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e380-e385.	imaging	0.7	28
589	Cervical Cancer with Intermediate Risk Factors: Is there a Role for Adjuvant Radiothera Systematic Review and a Meta-Analysis. Gynecologic and Obstetric Investigation, 2019	ру? А 9, 84, 606-615.	0.7	14
590	Value of diffusion-weighted and dynamic contrast-enhanced MR in predicting paramet cervical stromal ring focally disrupted stage IB–IIA cervical cancers. Abdominal Radic 3166-3174.	rial invasion in logy, 2019, 44,	1.0	4
591	PET/MR Imaging of the Female Pelvis. Seminars in Nuclear Medicine, 2019, 49, 512-52	0.	2.5	10
592	Cervical Squamous Neoplasia. , 2019, , 293-324.			1
594	Prognostic factors for and pattern of lymph-node involvement in patients with operabl cancer. Archives of Gynecology and Obstetrics, 2019, 300, 1709-1718.	le cervical	0.8	16
595	Vaginal cuff brachytherapy in the adjuvant setting for patients with high-risk early-stag cancer. Brachytherapy, 2019, 18, 747-752.	ge cervical	0.2	11

	CITATION REF	CITATION REPORT	
#	Article	IF	CITATIONS
596	Redistribution of Cervix Cancer Patients from FIGO 2009 to FIGO 2018 Staging Following Incorporation of Medical Imaging. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.1	0
597	Prediction of 10-year Overall Survival in Patients with Operable Cervical Cancer using a Probabilistic Neural Network. Journal of Cancer, 2019, 10, 4189-4195.	1.2	7
598	Gynecologic Cancer Survivorship. Obstetrics and Gynecology Clinics of North America, 2019, 46, 165-178.	0.7	27
600	Cervical cancer recurrence: Proposal for a classification based on anatomical dissemination pathways and prognosis. Surgical Oncology, 2019, 30, 40-46.	0.8	9
601	Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 342-350.	1.8	5
602	The Prognostic Impact of Grading in FIGO IB and IIB Squamous Cell Cervical Carcinomas. Geburtshilfe Und Frauenheilkunde, 2019, 79, 198-204.	0.8	9
603	Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer. Gynecologic Oncology, 2019, 153, 255-258.	0.6	10
604	SLN mapping in early-stage cervical cancer as a minimal-invasive triaging tool for multimodal treatment. European Journal of Surgical Oncology, 2019, 45, 679-683.	0.5	11
605	The value of pretreatment serum butyrylcholinesterase level as aÂnovel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy. Strahlentherapie Und Onkologie, 2019, 195, 430-440.	1.0	9
606	Transabdominal Doppler ultrasound evaluation of blood flow patterns of the uterine arteries in cervical cancer patients in Zaria, North-Western Nigeria. Annals of African Medical Research, 2019, 2, .	0.1	0
608	The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer. Nuclear Medicine Communications, 2019, 40, 219-227.	0.5	9
609	Updates and Controversies of Robotic-Assisted Surgery in Gynecologic Surgery. Clinical Obstetrics and Gynecology, 2019, 62, 733-748.	0.6	29
610	Nouvelle classification et recommandation de prise en charge du cancer du col de l'utérus selon la Fédération internationale de gynécologie obstétrique (FIGO). Imagerie De La Femme, 2019, 29, 187-194	.0.0	1
611	Multiâ€institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: A Kansai Clinical Oncology Group study (KCOGâ€G1201). Journal of Obstetrics and Gynaecology Research, 2019, 45, 671-678.	0.6	18
612	Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group. European Journal of Surgical Oncology, 2019, 45, 659-665.	0.5	20
613	Prognostic relevance of low-grade versus high-grade FIGO IB1 squamous cell uterine cervical carcinomas. Journal of Cancer Research and Clinical Oncology, 2019, 145, 457-462.	1.2	9
614	Cytomorphological features of highâ€grade intraepithelial neoplasia/carcinoma of the cervix following chemoradiotherapy. Diagnostic Cytopathology, 2019, 47, 194-199.	0.5	0
615	Uterine Cervical Cancer. , 2019, , .		3

#	Article	IF	CITATIONS
616	Cervical cancer. Lancet, The, 2019, 393, 169-182.	6.3	1,367
617	Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. International Journal of Clinical Oncology, 2019, 24, 1-19.	1.0	106
618	Artificial neural network based screening of cervical cancer using a hierarchical modular neural network architecture (HMNNA) and novel benchmark uterine cervix cancer database. Neural Computing and Applications, 2019, 31, 2979-2993.	3.2	18
619	Cancers of the Cervix, Vulva, and Vagina. , 2020, , 1468-1507.e8.		5
620	Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. American Journal of Obstetrics and Gynecology, 2020, 222, 484.e1-484.e15.	0.7	16
621	Fertility-Sparing Approaches in Gynecologic Oncology. Radiologic Clinics of North America, 2020, 58, 401-412.	0.9	12
622	Prognostic factors affecting survival and recurrence in patients with early cervical squamous cell cancer following radical hysterectomy. Journal of International Medical Research, 2020, 48, 030006051988974.	0.4	6
623	Distribution patterns of lymph node metastasis in early stage invasive cervical cancer. Medicine (United States), 2020, 99, e22285.	0.4	4
624	FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1248-1256.	0.4	15
625	The clinical and prognostic implication of deep stromal invasion in cervical cancer patients undergoing radical hysterectomy. Journal of Cancer, 2020, 11, 7368-7377.	1.2	12
626	Validation of the 2018 FIGO Classification for Cervical Cancer: Lymphovascular Space Invasion Should Be Considered in IB1 Stage. Cancers, 2020, 12, 3554.	1.7	19
627	Prognostic Assessment of Cervical Cancer Patients by Clinical Staging and Surgical-Pathological Factor: A Support Vector Machine-Based Approach. Frontiers in Oncology, 2020, 10, 1353.	1.3	12
628	Tumor budding in cervical cancer as a prognostic factor and its possible role as an additional intermediate-risk factor. Gynecologic Oncology, 2020, 159, 157-163.	0.6	15
629	Disparities in the Use of Adjuvant External Beam Radiation Therapy in Node-positive Cervical Cancer Patients Following Hysterectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 43-46.	0.6	4
630	Uterine cervical squamous cell carcinoma with reactive multinucleated giant cells expressing cluster of differentiation 204: A case report and literature review. Journal of Obstetrics and Gynaecology Research, 2020, 46, 2174-2178.	0.6	2
631	Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer. Pharmaceutics, 2020, 12, 987.	2.0	6
632	2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging. Radiographics, 2020, 40, 1807-1822.	1.4	40
633	The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer. Journal of Clinical Medicine, 2020, 9, 2960.	1.0	2

#	Article	IF	CITATIONS
634	Risk Stratification Based on Metastatic Pelvic Lymph Node Status in Stage IIIC1p Cervical Cancer. Cancer Management and Research, 2020, Volume 12, 6431-6439.	0.9	9
635	Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experience. Gynecologic Oncology, 2020, 159, 359-364.	0.6	5
636	Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Cancers, 2020, 12, 1115.	1.7	4
637	Surgical management of a case of recurrent carcinoma cervix: a case report. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2020, 9, 1721.	0.0	0
638	Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2020, 10, 220-234.	1.1	144
639	Prognostic value of lymphovascular space invasion in early-stage cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 1493-1499.	1.2	13
640	Evaluation of Parametrial Status in Locally Advanced Cervical Cancer Patients after Neoadjuvant Chemotherapy: A Prospective Study on Diagnostic Accuracy of Three-Dimensional Transvaginal Ultrasound. Oncology, 2020, 98, 603-611.	0.9	4
641	Micrometastases in Sentinel Lymph Nodes Represent a Significant Negative Prognostic Factor in Early-Stage Cervical Cancer: A Single-Institutional Retrospective Cohort Study. Cancers, 2020, 12, 1438.	1.7	16
642	<i>Dioscorea nipponica</i> Makino suppresses <scp>TPA</scp> â€induced migration and invasion through inhibition of matrix metalloproteinaseâ€9 in human cervical cancer cells. Environmental Toxicology, 2020, 35, 1194-1201.	2.1	8
643	Should the Number of Metastatic Pelvic Lymph Nodes Be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?. Cancers, 2020, 12, 1552.	1.7	24
644	The Safety and Efficacy of Intra-Arterial versus Intravenous Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer: A Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-7.	0.5	2
645	Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy. Gynecologic Oncology, 2020, 157, 423-428.	0.6	20
646	Prognostic factors influencing pelvic, extra-pelvic, and intraperitoneal recurrences in lymph node-negative early-stage cervical cancer patients following radical hysterectomy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 94-99.	0.5	2
647	Diagnostic value of frozen section examination of sentinel lymph nodes in early-stage cervical cancer at the time of ultrastaging. Gynecologic Oncology, 2020, 158, 576-583.	0.6	24
648	E2F8 regulates the proliferation and invasion through epithelial-mesenchymal transition in cervical cancer. International Journal of Biological Sciences, 2020, 16, 320-329.	2.6	20
649	Lymph Node Ratio Can Better Predict Prognosis than Absolute Number of Positive Lymph Nodes in Operable Cervical Carcinoma. Oncology Research and Treatment, 2020, 43, 87-95.	0.8	7
650	Integrated pre-surgical diagnostic algorithm to define extent of disease in cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 16-20.	1.2	7
651	European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 3-14.	1.2	39

#	Article	IF	CITATIONS
652	Does small volume metastatic lymph node disease affect long-term prognosis in early cervical cancer?. International Journal of Gynecological Cancer, 2020, 30, 285-290.	1.2	19
653	Impact of sentinel lymph node frozen section evaluation to avoid combined treatment in early-stage cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 744-748.	1.2	9
654	British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 433-465.	0.5	41
655	A bibliometric analysis of obstetrics and gynecology articles with highest relative citation ratios, 1980 to 2019. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100293.	1.3	18
656	Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 52-58.	1.2	22
657	Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery. British Journal of Cancer, 2021, 124, 1121-1129.	2.9	7
658	Extended field or pelvic intensity-modulated radiotherapy with concurrent cisplatin chemotherapy for the treatment of post-surgery multiple pelvic lymph node metastases in cervical cancer patients: a randomized, multi-center phase II clinical trial. Translational Cancer Research, 2021, 10, 361-371.	0.4	0
659	Current treatment modalities in major gynecologic cancers: Emphasis on response rates. , 2021, , 127-154.		0
660	Clinical features that affect the number of pelvic lymph nodes harvested in patients with cervical cancer stage IB1 to IIA2. Obstetrics and Gynecology Science, 2021, 64, 73-79.	0.6	0
661	Validation of the FIGO 2018 staging system of cervical cancer: Retrospective analysis of FIGO 2009 stage IB1 cervical cancer with tumor under 2 cm. Journal of Obstetrics and Gynaecology Research, 2021, 47, 1871-1877.	0.6	4
662	Endocervical Adenocarcinoma, Gross Examination, and Processing, Including Intraoperative Evaluation: Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 2021, 40, S24-S47.	0.9	7
663	Post-operative small pelvic field radiation therapy in patients with intermediate risk early stage cervix cancer: a safe and efficient treatment modality. Reports of Practical Oncology and Radiotherapy, 2021, 26, 360-366.	0.3	1
664	Prognostic Factors Associated with 5-Year Overall Survival in Cervical Cancer Patients Treated with Radical Hysterectomy Followed by Adjuvant Concurrent Chemoradiation Therapy at a Tertiary Care Center in Eastern Europe. Diagnostics, 2021, 11, 570.	1.3	10
665	Prognostic significance of poorly differentiated histology and impact of adjuvant chemotherapy in early squamous cell carcinoma of cervix uteri. Cancer Medicine, 2021, 10, 2611-2617.	1.3	2
666	Cancer du col utérinÂ: nouvelle classification de la Fédération internationale de gynécologie et d'obstétrique. Imagerie De La Femme, 2021, 31, 30-39.	0.0	1
667	Sequential Chemotherapy for Early-Stage, Post–Radical Hysterectomy Cervical Cancer. JAMA Oncology, 2021, 7, 353.	3.4	1
668	Evidence for disseminated tumor cells in lymphatic vessels afferent to sentinel lymph nodes in patients diagnosed with cervical cancer. Cancer Reports, 2021, 4, e1366.	0.6	1
669	The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer. Gynecologic Oncology, 2021, 161, 166-172.	0.6	7

#	Article	IF	CITATIONS
670	Fertility-Saving Surgery for Gynecological Cancers. , 2021, , 187-196.		0
671	Analysis of the prognostic factors determining the oncological outcomes in patients with high-risk early-stage cervical cancer. Journal of Obstetrics and Gynaecology, 2022, 42, 281-288.	0.4	4
672	Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2). European Journal of Cancer, 2021, 148, 307-315.	1.3	61
673	Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States. International Journal of Gynecological Cancer, 2021, 31, 991-1000.	1.2	7
674	Survival Outcomes in Patients With 2018 FIGO Stage IA2–IIA2 Cervical Cancer Treated With Laparoscopic Versus Open Radical Hysterectomy: A Propensity Score-Weighting Analysis. Frontiers in Oncology, 2021, 11, 682849.	1.3	4
675	A Novel Dialkylamino-Functionalized Chalcone, DML6, Inhibits Cervical Cancer Cell Proliferation, In Vitro, via Induction of Oxidative Stress, Intrinsic Apoptosis and Mitotic Catastrophe. Molecules, 2021, 26, 4214.	1.7	3
676	Adjuvant Radiotherapy After Minimally Invasive Surgery in Patients With Stage IA1-IIA1 Cervical Cancer. Frontiers in Oncology, 2021, 11, 690777.	1.3	2
677	Adjuvant treatment in cervical, vaginal and vulvar cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 78, 36-51.	1.4	10
678	Useful MRI Findings for Minimally Invasive Surgery for Early Cervical Cancer. Cancers, 2021, 13, 4078.	1.7	7
679	The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients. Gynecologic Oncology, 2021, 162, 299-307.	0.6	25
680	iPMI: Machine Learning-Aided Identification of Parametrial Invasion in Women with Early-Stage Cervical Cancer. Diagnostics, 2021, 11, 1454.	1.3	7
681	Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecologic Oncology, 2021, 162, 532-538.	0.6	22
682	Variability in the identification of lymphovascular space invasion for early stage cervical cancer. Surgical Oncology, 2021, 38, 101566.	0.8	4
683	Successful pregnancy with stage IB2 uterine cervical cancer: A case report. Cancer Reports, 2021, , e1542.	0.6	1
684	The significance of post-radiotherapy parametrial involvement and the necessity of parametrial resection in locally-recurrent or persistent cervical cancer developed after radiotherapy. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102190.	0.6	4
685	Malignant diseases of the cervix. , 2022, , 674-690.e3.		0
686	Principle of Radiation Therapy for Gynaecologic Cancers. , 2021, , 655-661.		0
687	A low preoperative albumin-to-globulin ratio is a negative prognostic factor in patients with surgically treated cervical cancer. International Journal of Clinical Oncology, 2021, 26, 980-985.	1.0	9

#	ARTICLE Carcinoma and Other Tumors of the Cervix. , 2011, , 253-303.	IF	Citations 8
689	Advances in the treatment of cervical cancer. Cancer Treatment and Research, 1998, 95, 149-176.	0.2	3
690	Processing and Histopathological Workup of Hysterectomy Specimens. , 2018, , 259-295.		1
691	Gynecologic Tumors. Recent Results in Cancer Research, 2008, 170, 141-150.	1.8	7
692	Cervical Center. Medical Radiology, 2007, , 121-179.	0.0	1
693	Cancer of the Cervix. Medical Radiology, 1997, , 143-239.	0.0	5
694	Carcinoma of the Cervix and Endometrium. , 2002, , 523-548.		6
696	Cancers of the Cervix, Vulva, and Vagina. , 2008, , 1745-1791.		2
697	Cancers of the Cervix, Vulva, and Vagina. , 2014, , 1534-1574.e8.		7
698	MAGNETIC RESONANCE IMAGING APPLICATIONS IN UTERINE CERVICAL CANCER. Magnetic Resonance Imaging Clinics of North America, 1994, 2, 211-243.	0.6	15
699	Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. International Journal of Gynecological Cancer, 2000, 10, 305-312.	1.2	106
700	The significance of tumor size in clinical stage IB cervical cancer: Can a cut-off figure be determined?. International Journal of Gynecological Cancer, 2000, 10, 397-401.	1.2	10
701	Loss of Heterozygosity and Copy Number Alterations in Flow-Sorted Bulky Cervical Cancer. PLoS ONE, 2013, 8, e67414.	1.1	7
702	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. Current Gynecologic Oncology, 2017, 15, 5-23.	0.1	16
703	Intensity of cervical inflammatory reaction as a risk factor for recurrence of carcinoma of the uterine cervix in stages IB and IIA. Sao Paulo Medical Journal, 2007, 125, 231-236.	0.4	7
704	Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. Oncotarget, 2017, 8, 106866-106875.	0.8	30
705	Perineural invasion in cervical cancer: pay attention to the indications of nerve-sparing radical hysterectomy. Annals of Translational Medicine, 2019, 7, 203-203.	0.7	16
706	Cyr61 Expression Pattern and Association with Clinicopathological Factors in Patients with Cervical Cancer. Anticancer Research, 2017, 37, 2451-2456.	0.5	7

#	Article	IF	CITATIONS
707	Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review. Anticancer Research, 2017, 37, 2487-2490.	0.5	3
708	The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy. Journal of Gynecologic Oncology, 2020, 31, e1.	1.0	27
709	Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor. Journal of Gynecologic Oncology, 2020, 31, e35.	1.0	19
710	Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer. Radiation Oncology Journal, 2015, 33, 126.	0.7	16
711	The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04). Cancer Research and Treatment, 2018, 50, 964-974.	1.3	41
712	Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028). Cancer Research and Treatment, 2020, 52, 320-333.	1.3	19
713	Sentinel lymph nodes and planar scintigraphy and SPECT/CT in various types of tumours. Estimation of some factors influencing detection success. Nuclear Medicine Review, 2013, 16, 17-25.	0.3	21
714	Current Concepts in Cervical Pathology. Archives of Pathology and Laboratory Medicine, 2009, 133, 729-738.	1.2	39
715	Prognostic Model in Patients with Early-stage Squamous Cell Carcinoma of the Uterine Cervix: A Combination of Invasive Margin Pathological Characteristics and Lymphovascular Space Invasion. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6935-6940.	0.5	9
716	Locoregional Spread and Survival of Stage IIA1 versus Stage IIA2 Cervical Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 887-890.	0.5	9
717	Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer. PeerJ, 2019, 7, e7804.	0.9	16
718	Prediction of Recurrence in Patients with Cervical Cancer Using MARS and Classification. International Journal of Machine Learning and Computing, 2013, , 75-78.	0.8	13
719	Comparison of treatment outcomes of pelvis external radiotherapy with and without vaginal brachytherapy for cervical cancer patients with positive or close vaginal resected margins. International Journal of Clinical Oncology, 2022, 27, 202-212.	1.0	1
720	Predicting Tumor Budding Status in Cervical Cancer Using MRI Radiomics: Linking Imaging Biomarkers to Histologic Characteristics. Cancers, 2021, 13, 5140.	1.7	5
721	Cancer of the cervix uteri: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 28-44.	1.0	153
722	Cervical Cancer and Fertility-Sparing Treatment. Journal of Clinical Medicine, 2021, 10, 4825.	1.0	9
723	MR IMAGING OF FEMALE PELVIC MALIGNANCIES. Magnetic Resonance Imaging Clinics of North America, 2000, 8, 887-914.	0.6	9
724	Zervixkarzinom. Spezielle Pathologische Anatomie, 2001, , 333-406.	0.0	0

#	Article	IF	CITATIONS
725	Zervixkarzinom. , 2002, , 677-711.		0
726	Therapie des Zervixkarzinoms bei der Ĥeren Frau. , 2002, , 29-42.		0
727	Diagnose und Therapie des Zervixkarzinoms. , 2002, , 114-123.		1
728	Cervical, Vulvar, and Vaginal Cancer. , 2003, , 545-561.		0
729	Cancer of the Uterus. , 2004, , 237-241.		0
730	Cancers of Vulvar, Vaginal, and Cervical Cancers. , 2004, , 47-68.		0
731	Zervixkarzinom. , 2004, , 1113-1151.		0
732	Zervixkarzinom. , 2006, , 4616-4743.		0
733	Treatment of Cervical Cancer. Journal of the Korean Medical Association, 2007, 50, 785.	0.1	0
734	Mammakarzinom und gynäologische Malignome. , 2007, , 745-832.		0
736	Utilização da ressonância magnética para o planejamento radioterápico dos tumores de colo de útero. Radiologia Brasileira, 2008, 41, 418-418.	0.3	0
738	Clinicopathological Analysis of Lymphatic Vessels and of Lymphangiogenesis in Human Cancer. Cancer Metastasis - Biology and Treatment, 2009, , 119-158.	0.1	0
739	Patterns of Spread of Gynecologic Disease. , 2010, , 347-361.		0
740	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
741	Mammakarzinom und gynÄ k ologische Malignome. , 2012, , 723-803.		0
742	Lymphatic mapping and laparoscopic sentinel node biopsy in early cervical cancer. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2012, 28, 603-607.	0.0	0
745	A case of advanced uterine cervical carcinoma with a huge retroperitoneal lymph node metastasis that was difficult to diagnose before surgery. The Journal of the Japanese Society of Clinical Cytology, 2014, 53, 200-205.	0.0	0
746	Cervix Uteri Carcinoma. , 1995, , 185-192.		6

#	ARTICLE	IF	CITATIONS
747	Zervixkarzinom. , 1997, , 1168-1198.		0
748	Advances in the radiotherapy of gynecologic malignancies. Cancer Treatment and Research, 1998, 95, 177-201.	0.2	0
749	Maligne Tumoren der Cervix uteri. , 1998, , 147-186.		0
750	Cervical, Vulvar, and Vaginal Cancer. , 1999, , 869-886.		0
751	Selection of Surgery or Radiotherapy as the Appropriate Single Modality of Treatment for Stage 1B and 2A Carcinoma of the Cervix. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1999, 39, 85-87.	0.4	0
753	Radiation Therapy in Gynecologic Cancer. , 2015, , 289-334.		0
755	The Role of Radiation Therapy in the Treatment of Malignant Gynecological Tumors. , 2015, , 3-40.		0
756	Mammakarzinom und gynÃkologische Malignome. , 2015, , 759-839.		0
757	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
758	An Audit of 204 Histopathology Reports Over Three Years of Carcinoma of Cervix: Experience from a Tertiary Referral Centre. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5643-5645.	0.5	0
759	Early Stage Cervical Cancer, Therapy for Reproductive Health and Quality Survival. Open Medicine Journal, 2016, 3, 1-11.	0.5	3
760	Role of Skeletal Scintigraphy in Evaluation of Low Backache in Treated Cases of Carcinoma Cervix. Journal of Medical Science and Clinical Research, 0, , .	0.0	0
761	Mixed Adenosquamous Histology is Associated with Poorer Survival of Cervical Cancer Stage 1b. International Journal of Cancer Studies & Research, 0, , 98-101.	0.0	0
762	Radiotherapy in Cervical Cancer. , 2017, , 177-197.		0
763	Surgical and Nonsurgical Management of Cervical Cancer: Current Practice and Future Directions. , 2017, , 67-77.		0
764	Management of Early-Stage and Locally Advanced Cervical Cancer. , 2017, , 845-852.		0
765	Analysis of treatment failures in stage IB–IIA squamous cell carcinoma of the uterine cervix following surgery. Current Gynecologic Oncology, 2017, 15, 54-67.	0.1	0
766	Prognostic Factors and Treatment Outcome in 178 Locally Advanced Cervical Cancer Patients. Open Journal of Obstetrics and Gynecology, 2018, 08, 485-496.	0.1	0

#	ARTICLE	IF	CITATIONS
767	Approach and Management of Cervical Cancer. , 2019, , 491-549.		0
768	Survival outcomes of low-risk and intermediate-risk stage IB1 cervical cancer patients. Asian Biomedicine, 2019, 13, 27-32.	0.2	0
769	Long-Term Follow-Up Outcomes of Cervical Cancer Patients: A Single Center Experience from the East Anatolian Region of Turkey. Dicle Medical Journal, 2019, 46, 857-865.	0.2	2
770	Validated limited gene predictor for cervical cancer lymph node metastases. Oncotarget, 2020, 11, 2302-2309.	0.8	2
771	Prognostic Value of Lymph Node Characteristics in Patients with Cervical Cancer Treated with Radical Hysterectomy. Cancer Management and Research, 2021, Volume 13, 8137-8145.	0.9	4
772	Critical Remarks to Endoscopic Surgery for Endometrial Cancer and Sarcoma, Cervical and Ovarian Cancer Diagnosis and Treatment. Novel Approaches in Cancer Study, 2020, 4, .	0.2	Ο
773	Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. Frontiers in Oncology, 2021, 11, 770103.	1.3	2
774	PET and PET/CT Imaging in Testicular and Gynecologic Cancers. , 2006, , 217-231.		0
775	Prise en charge actuelle du carcinome invasif du col utérin (hors récidive). , 2007, , 277-290.		0
776	Genome-wide screening of DNA copy number alterations in cervical carcinoma patients with CGH+SNP microarrays and HPV-FISH. International Journal of Clinical and Experimental Pathology, 2014, 7, 5071-82.	0.5	5
777	Heparanase promotes radiation resistance of cervical cancer by upregulating hypoxia inducible factor 1. American Journal of Cancer Research, 2017, 7, 234-244.	1.4	9
778	Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer. Nagoya Journal of Medical Science, 2017, 79, 211-220.	0.6	6
779	CD147 promotes cervical cancer migration and invasion by up-regulating fatty acid synthase expression. International Journal of Clinical and Experimental Pathology, 2019, 12, 4280-4288.	0.5	5
780	DLEU2 participates in lymphovascular invasion and inhibits cervical cancer cell proliferation, migration, and invasion. International Journal of Clinical and Experimental Pathology, 2020, 13, 2018-2026.	0.5	0
781	An MRI-based radiomics signature and clinical characteristics for survival prediction in early-stage cervical cancer. British Journal of Radiology, 2022, 95, 20210838.	1.0	10
782	Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study. Cancers, 2022, 14, 212.	1.7	7
783	microRNA Profile Associated with Positive Lymph Node Metastasis in Early-Stage Cervical Cancer. Current Oncology, 2022, 29, 243-254.	0.9	4
784	Volumetric PET parameters are predictive for the prognosis of locally advanced cervical cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, , .	0.4	0

#	Article	IF	CITATIONS
785	Long term outcomes of patients who underwent radical hsyterectomy for cervical cancer. Journal of Health Sciences and Medicine, 2022, 5, 239-246.	0.0	0
786	The Clinical Aspects and Prognostic Factors Concerning Survival in Patients With Recurrent Cervical Cancer After Radical Hysterectomy and Adjuvant Chemoradiotherapy. Frontiers in Oncology, 2021, 11, 782403.	1.3	1
787	Oncologic outcomes according to the level of disease burden in patients with metachronous distant metastases from uterine cervical cancer: a Korean Radiation Oncology Group study (KROG 18-10). Journal of Gynecologic Oncology, 2022, 33, .	1.0	1
788	Neoadjuvant Chemotherapy Prior Fertility-Sparing Surgery in Women with FIGO 2018 Stage IB2 Cervical Cancer: A Systematic Review. Cancers, 2022, 14, 797.	1.7	8
789	Postoperative adjuvant radiation for cervix cancer: reflections on the evidence and a peep into the future. International Journal of Gynecological Cancer, 2022, 32, 225-230.	1.2	3
790	Improving Radiation Therapy for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 841-848.	0.4	2
791	MRI-based radiomics analysis to evaluate the clinicopathological characteristics of cervical carcinoma: a multicenter study. Acta Radiologica, 2023, 64, 395-403.	0.5	3
792	Significance of the Number of Intermediate-Risk Factors in Cervical Cancer Patients Treated with Radical Hysterectomy: A Retrospective Study of 976 Patients. Journal of Investigative Surgery, 2022, 35, 1098-1105.	0.6	4
793	Retrospective analysis of prognosis using the Gynecology Oncology Group score of stage IB‑IIA node negative uterine cervical cancer after radical hysterectomy and trachelectomy. Molecular and Clinical Oncology, 2022, 16, .	0.4	1
794	Adjuvant therapy in early-stage cervical cancer after radical hysterectomy: are we overtreating our patients? A meta-analysis. Clinical and Translational Oncology, 2022, , 1.	1.2	5
795	Cervix: squamous cell carcinoma and precursors. , 0, , 19-33.		0
797	The Relationship Between Parametrial Involvement and Parametrial Tissue Removed in Radical Surgery in Early-Stage Cervical Cancer. World Journal of Oncology, 2022, 13, 59-68.	0.6	2
798	Pretreatment Radiologically Enlarged Lymph Nodes as a Significant Prognostic Factor in Clinical Stage IIB Cervical Cancer: Evidence from a Taiwanese Tertiary Care Center in Reaching Consensus. Diagnostics, 2022, 12, 1230.	1.3	7
799	Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies. Cancers, 2022, 14, 2449.	1.7	10
800	Down-regulated expression of miR-99a is associated with lymph node metastasis and predicts poor outcome in stage IB cervical squamous cell carcinoma: a case-control study. Annals of Translational Medicine, 2022, 10, 663-663.	0.7	4
801	Results of laparoscopic pelvic exenterations. Khirurgiya, 2022, , 45.	0.0	0
802	The pathological risk score: A new deep learningâ€based signature for predicting survival in cervical cancer. Cancer Medicine, 2023, 12, 1051-1063.	1.3	13
803	No impact of tumor size on oncological outcomes in cervical cancer patients after radical hysterectomy and postoperative radiotherapy: Is it real?. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 575-577.	0.5	11

#	Article	IF	CITATIONS
804	Significance of the Number and the Location of Metastatic Lymph Nodes in Locally Recurrent or Persistent Cervical Cancer Patients Treated with Salvage Hysterectomy plus Lymphadenectomy. Current Oncology, 2022, 29, 4856-4867.	0.9	1
805	Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer. Journal of Computer Assisted Tomography, 2022, 46, 707-715.	0.5	3
806	Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. The Cochrane Library, 2022, 2022, .	1.5	41
807	Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382211181.	0.8	0
808	Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?. International Journal of Gynecological Cancer, 2022, 32, 1219-1226.	1.2	10
810	A novel Silva pattern-based model for precisely predicting recurrence in intermediate-risk cervical adenocarcinoma patients. BMC Women's Health, 2022, 22, .	0.8	1
811	Fertility-Sparing Treatment for Early-Stage Cervical CancerÂ≥Â2Âcm: A Problem with a Thousand Nuances—A Systematic Review of Oncological Outcomes. Annals of Surgical Oncology, 2022, 29, 8346-8358.	0.7	5
812	Dataset for the Reporting of Carcinoma of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology, 2022, 41, S64-S89.	0.9	12
814	Invasive cervical cancer. , 2023, , 40-103.e16.		0
815	Impact of lymphadenectomy in patients with locally recurrent or persistent cervical cancer treated with salvage hysterectomy. Journal of Obstetrics and Gynaecology Research, 0, , .	0.6	1
817	Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection. Gynecologic Oncology, 2023, 169, 91-97.	0.6	0
818	Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial. Frontiers of Medicine, 2023, 17, 93-104.	1.5	4
819	Oncologic outcome in patients with 2018 FIGO stage IB cervical cancer: Is tumor size important?. Journal of Obstetrics and Gynaecology Research, 0, , .	0.6	0
820	Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial. BMC Cancer, 2022, 22, .	1.1	3
821	Management of Early-Stage and Locally Advanced Cervical Cancer. , 2023, , 1-11.		0
823	Adjuvant pelvic radiation versus observation in intermediate-risk early-stage cervical cancer patients following primary radical surgery: a propensity score-adjusted analysis. Journal of Gynecologic Oncology, 0, 34, .	1.0	1
824	Impact of different postoperative adjuvant therapies on the survival of earlyâ€stage cervical cancer patients with one intermediateâ€risk factor: A multicenter study of 14 years. Journal of Obstetrics and Gynaecology Research, 2023, 49, 1579-1591.	0.6	6
835	Management of Early-Stage and Locally Advanced Cervical Cancer. , 2023, , 989-999.		0

#	Article	IF	CITATIONS
844	Postoperative Adjuvant Therapy for Cervical Cancer. Comprehensive Gynecology and Obstetrics, 2024, , 175-187.	0.0	0